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Background: Individuals living in high-poverty areas are more likely to develop cancers 
associated with human papillomavirus (HPV). Evidence also suggests that high-poverty counties 
also have higher uptake of HPV vaccine, but the effect of HPV vaccine on cancer disparities by 
area poverty remains unknown.  
Methods: We constructed a dynamic infection model of HPV transmission that we 
modified to incorporate HPV prevalence, HPV cancer incidence, and HPV vaccination specific 
to low- and high-poverty counties. We created a synthetic population projecting the absolute and 
relative change in HPV cancer incidence in high- vs. low-poverty counties over a 75-year time 
horizon, as well as the potential cost and outcomes associated with increasing vaccination rates 
by 10% in each setting. Finally, we examined the cost-effectiveness of three evidence-based 
interventions designed to increase HPV vaccine uptake; school located vaccination, the 
Assessment, Feedback, Incentives and eXchange program, and a centralized reminder/recall 
intervention.  
Results: We find HPV vaccination will dramatically reduce annual incidence of HPV 
cancers in both low- and high-poverty counties, but HPV cancer disparities by area poverty 
would remain relatively unchanged with slight decreases among women and little to no change 
in disparities among males. We also find that increases in HPV vaccine would produce greater 
absolute reductions in HPV cancers in high- vs. low-poverty settings, resulting in an incremental 
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cost effectiveness in high-poverty counties that is nearly half that of low-poverty counties. 
Finally, we show that all three strategies to improve HPV vaccine uptake are cost-effective 
relative to status quo. The AFIX program is the lowest total cost and vaccination increase while a 
large-scale school-located HPV vaccination program is both the most effective and most costly 
alternative. 
Discussion: HPV vaccine offers unprecedented potential to prevent HPV cancers but is 
underutilized in the US. Policy-makers seeking to reduce cancer disparities by area poverty 
should prioritize increasing HPV vaccine uptake as part of a multi-component strategy including 
addressing care access and social determinants of HPV cancer. As HPV vaccination falls below 
standard cost-effectiveness thresholds, considerable resources could be dedicated to increasing 
vaccine uptake, particularly in settings with high HPV cancer burden, while maintaining net 
societal benefit.  
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CHAPTER 1: INTRODUCTION 
Background  
 Individuals living in high-poverty areas are more likely to develop and die from several 
cancers.1 Among those with the largest disparities by area poverty are cancers associated with 
human papillomavirus (HPV). For example, individuals living in high-poverty areas are nearly 
twice as likely to both develop and to die from cervical cancer as individuals in low-poverty 
areas.1,2 Incidence rates of penile, anal, vaginal, vulvar, and oropharyngeal cancer are also higher 
for those living in high-poverty areas.1 The socioeconomic divide in HPV cancer is likely 
complex and has been attributed to multiple, overlapping risk factors.3 Among these are 
differences in health behaviors, sexual networks and preventive care.4 In 2006, the introduction 
of HPV vaccine created an important opportunity for cancer prevention, with the most recent 
version protecting against seven oncogenic types of HPV.5  
 HPV vaccination has unprecedented potential to reduce not only mortality, but incidence of 
many cancers and precancerous lesions attributable to HPV. The reduction in cancer incidence is 
expected to be particularly dramatic in cervical cancer, leading the American Association of 
Cancer Research and others to declare the eradication of cervical cancer an achievable goal.6–9 
However, high incidence rates of cervical and other HPV cancers in low-resource areas of the 
US may make universal eradication harder to accomplish.  
 HPV vaccination has the potential to reduce disparities in cancer outcomes by providing 
accessible prevention at a low out-of-pocket cost. Currently, initiation (first receipt) of HPV 
 
 2 
vaccine is actually higher for teens living below the Federal Poverty Level (FPL) (73%) than 
those individuals living above the FPL (63%) with no significant differences in rates of vaccine 
follow-through (subsequent administrations among initiators).10 This leads to those below FPL 
being more likely to be fully up-to-date with all recommended doses (54% vs. 47%). The same 
pattern has been described for HPV vaccination using area-level measures of socioeconomic 
conditions.11,12 The higher rate of HPV vaccine uptake in economically deprived settings is 
poorly understood, but has been attributed to publicly funded vaccine programs (including the 
Vaccines for Children Program) and successful outreach from community health centers.11 
Regardless of the underlying mechanism of higher uptake in traditionally underserved counties, 
the long-term implications of this phenomenon for disparities in cancer incidence for high- and 
low-poverty counties remain unexplored. Simulation models have been constructed to assess the 
overall impact of HPV vaccination on cancer burden13–15 but, to date, these models have not 
considered the geographic heterogeneity of vaccination rates, HPV burden, and screening 
behavior across US counties.  
 Simulation models have also been used to evaluate the cost-effectiveness of HPV 
vaccination.  Even prior to the Food and Drug Administration (FDA) approval of the vaccine, 
researchers used modeling methods to assess the potential of HPV vaccination for cancer 
reduction and a formulation protecting against HPV 16 and HPV 18 would be cost-effective for 
prevention of cervical cancer.16 After FDA approval in 2006, Kim and Goldie re-evaluated cost-
effectiveness estimates of the quadrivalent vaccine, incorporating additional benefits of 
vaccination- such as protection against genital warts.17  
 As evidence of effectiveness of HPV vaccination changed and formulations improved, both 
modeling studies and policy recommendations changed as well. As trials showed HPV vaccine to 
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be efficacious against additional cancers in both men and women18–20, the American Committee 
on Immunization Practices (ACIP) expanded their routine recommendation to both boys and 
girls 11-12 years of age.21 The cost-effectiveness of HPV vaccination among boys varies widely 
by assumptions around vaccine uptake among women and whether models include male to male 
transmission.15,22–24  In 2015, the FDA approved a new formulation of HPV vaccine, which 
protects against nine types of the virus (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58).25 This nine-type 
version was soon added to ACIP recommendations.26  Modeling studies compared this 
formulation to the four type vaccine and found it to be a cost saving strategy.27,28 Lastly, in 2016 
a two-dose vaccination schedule was shown to be efficacious and was recommended for boys 
and girls initiating the vaccine prior to age 15.29,30 Even in the presence of increased per-dose 
cost, the net reduction in upfront costs for vaccination with little to no reduction in long-term 
benefit was cost-saving relative to the four-type version.31  
 Globally, modeling studies have examined thresholds needed for eliminating cervical 
cancer (reducing rates below 1 per 100,000) in both low and high-income countries and have 
found that while elimination may be feasible for high income countries, HPV vaccination alone 
would be insufficient for elimination in lower income countries by the end of the century.32–34 
Domestically, both research and advocacy organizations believe the eradication of cervical 
cancer may be an achievable goal through combinations of improving screening practices and 
increasing HPV vaccination.6,8,9 Yet despite the potential of HPV vaccination for reduction of 
HPV cancers, rates of uptake in the US are still much lower than the HealthyPeople 2020 target 
of 80%.35 Interventions to improve HPV vaccination rates have had mixed results36, but there has 
not been direct comparison of interventions, nor an understanding of the long-term cost-
effectiveness of these strategies.   
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 The overall objective of this study is to understand the implications of current geographic 
patterns of HPV vaccine uptake on HPV cancer incidence and to identify cost-effective strategies 




 Large and persistent income-related disparities exist in cancer incidence and cancer-related 
mortality within the US, with individuals living in high-poverty areas more likely to develop and 
die from multiple types of cancer- including those associated with HPV.2 Higher cervical cancer 
rates in low-resource areas are partially attributable to differences in access to timely receipt of 
Pap smears, which can prevent cervical cancer through the detection and subsequent treatment of 
pre-cancerous lesions.4 Even for HPV-associated cancers for which no effective screening exists, 
socioeconomic disparities are observed in both incidence and mortality.1  HPV vaccine now 
offers even earlier intervention by protecting against oncogenic types of the virus that cause 
cervical, anal, penile, vulvar, vaginal, and oropharyngeal cancers.21 Importantly, early evidence 
shows that HPV vaccine initiation rates may actually be higher for teens in high-poverty 
counties.11 HPV vaccine has the potential not to just reduce overall cancer incidence, but to 
reduce geographic disparities in HPV-associated cancers.  
 As HPV cancer incidence is far removed from administration of the vaccine itself, many 
studies assessing the potential effect of the vaccine necessarily rely on mathematical modeling 
methods.14,17,37 Beyond prediction of future trends, transmission models have also been used to 
compare multiple prevention strategies; assessing whether to include men in vaccination 
programs15,38–40, what age ranges should be targeted13,41, and how cervical cancer screening 
protocols should change as a result of the vaccine.14,42–44 As with studies predicting the effect of 
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the vaccines, these models used average population characteristics to assess baseline risk for 
HPV infection and HPV associated-cancer incidence. While some studies incorporated variation 
in observed HPV vaccine uptake into their models27,45, most examined outcomes at two or more 
levels of vaccine coverage- generally an ideal “high coverage” scenario (90-100% completion) 
and more realistic “low coverage” scenario (50-60% completion).38,44,46  Only in recent years 
have completion rates in the US begun to approach this “low coverage” estimate, in part due to a 
reduction in the number of required doses.30 Studies are also inconsistent in their assumptions 
around efficacy when the series is initiated but not completed, with some studies assuming no 
protection, some assuming partial protection, and some assuming complete protection.15,47–49 
Comparison of HPV vaccine completion rates as well as other model assumptions from several 
representative modeling studies are presented in the appendix (sTable 1).   
 While HPV vaccination has been studied across countries, examination of differential 
vaccination or outcomes for subpopulations within the US are less common. Burger and 
colleagues projected changes in racial disparities for HPV-related cancer incidence under both 
ideal and observed HPV vaccine uptake and found existing disparities are likely to decrease, but 
not disappear.45 It is worth noting, however, that while this model includes racial differences in 
vaccination, it is not dynamic and therefore only accounts for racial differences in HPV 
prevalence and cervical cancer screening practices indirectly, through including differences in 
observed cancer incidence. Another study from 2016 explores geographic disparities, finding 
high heterogeneity across states in the cost-effectiveness of the nine-type vaccine by 
incorporating state-level differences in current vaccination patterns, demographic characteristics, 
sexual behaviors, and cervical cancer screening rates.27  
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 To date, no studies have examined implications for HPV-associated cancer burden based 
on differences in HPV vaccination by area poverty. This difference is particularly important 
given a seemingly anomalous finding of higher HPV vaccination initiation in high-poverty 
areas.11  Area poverty has been associated with lower rates of Pap smear completion and higher 
rates of cervical and other HPV cancers.1,4 As a result, it is unclear how geographic disparities in 
HPV-associated cancers may change in the future as a result of current patterns of care. 
Understanding the long-term cancer implications of differences in vaccination is important for 
targeting effective interventions to populations with the highest need.  
 This research studies helps to identify how geographic differences in HPV-associated 
cancer will change as a result of current vaccination rates (initiation and completion), when 
considered in the context of existing patterns of HPV prevalence and cancer screening by area 
deprivation. Further, it examines the cost-effectiveness of strategies for increasing HPV 
vaccination from the perspective of a state government.    
Innovation 
 
 This dissertation offers novel insight into an important disparity in HPV cancer, through 
exploring the implications of differences in HPV vaccine receipt in high- and low-poverty 
counties. High rates of HPV vaccine initiation among lower income adolescents is an anomaly 
within cancer prevention efforts, and a better understanding of this phenomenon on a larger scale 
will help to target future strategies, not just for HPV-associated cancers, but for other primary 
prevention efforts. 
 Because HPV vaccine has not been in use long enough to assess its effects on cancer 
incidence directly, this study uses advanced decision modeling methods, namely system 
dynamics modeling, to project the effects of current vaccine initiation and completion rates on 
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future outcomes, considering differences in HPV infection, underlying risk factors for 
development of HPV cancers, and cervical cancer screening for high- and low-poverty counties. 
While other studies have used modeling techniques to assess the potential long-term outcomes of 
HPV vaccination, none have considered the implication of current vaccination patterns on 
geographic cancer disparities. These results will help to guide policy-makers by determining 
whether HPV vaccine will reduce cancer incidence as well as identifying cost-effective strategies 
for future HPV-associated cancer prevention efforts. 
Conceptual model  
 
 The proposed research is based on a modified version of Zapka’s Cancer Continuum 
Framework50, which examines how disparities arise at each step in the continuum of care, from 
risk assessment to cancer incidence (Figure 1). Zapka conceptualizes disparities as more than 
failures at one individual point, but as additive failures throughout a continuum which accrue 
over time to lead to lower quality outcomes. In cervical cancer, for example, multiple missed 
opportunities for prevention, later detection of cervical abnormalities, and delayed treatment lead 
to disparate outcomes for those of lower incomes. In other HPV-associated cancers, differences 
in risk assessment, exposure, and early detection may also exist. 51 
 I use this continuum to consider the effect of county poverty as a contributor to potential 
failures in cancer prevention over time. Aim 1 demonstrates how early intervention with HPV 
vaccination may influence HPV cancer incidence in the presence of other failures along the 
prevention pathway. Aim 2 assess the cost-effectiveness of improving one aspect of this 
continuum in two separate contexts (low-poverty counties and high-poverty counties). Aim 3 
considers the cost-effectiveness of interventions to increase HPV vaccination, considering the 




Figure 1: HPV Cancer Care Continuum 
 









CHAPTER 2: MODELING THE LONG-TERM IMPLICATIONS OF HPV 






Introduction: Individuals living in high-poverty areas are more likely to develop cancers 
associated with human papillomavirus (HPV). Evidence suggests high-poverty counties have 
also have higher uptake of HPV vaccine. HPV vaccination is projected to reduce the incidence of 
HPV cancers nationally, but it remains unknown if current vaccination rates will affect 
disparities in HPV cancer incidence in high- vs low-poverty US counties is unknown.  
Methods: We constructed a dynamic infection model of HPV transmission that we then 
modified to incorporate data on HPV prevalence, HPV cancer incidence, HPV vaccination, and 
cervical cancer screening specific to low- and high-poverty counties. We created a synthetic 
population of one million individuals in both a hypothetical low-poverty and hypothetical high-
poverty county and projected the absolute and relative change in HPV cancer incidence in high- 
vs. low-poverty counties over a 75-year time horizon.   
Results: Current vaccination coverage would reduce annual incidence of HPV cancers in 
both low- and high-poverty counties, but relative disparities in cancer would remain relatively 
unchanged. Prior to the introduction of HPV vaccine, those in high-poverty counties have an 
HPV cancer risk 1.51 times that of low-poverty counties. Projecting to 75 years after the 
introduction of HPV vaccine, the disparity decreases only slightly to a relative risk of 1.46. For 
HPV cancers among women, the disparity declines from a relative risk of 1.82 prior to HPV 
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vaccine introduction to a projected disparity of relative risk of 1.74 at 75 post-vaccination. For 
men, the relative HPV cancer disparity between high and low-poverty counties is projected to 
increase slightly (from 1.53 to 1.54).  
Discussion: We project a continuation of historically higher vaccination in high-poverty 
counties (relative to low-poverty counties) will be insufficient to meaningfully reduce HPV 
cancer disparities by county poverty. It is important to continue to increase HPV vaccination in 
all populations, but the US will also need a multi-faceted approach to address screening, 








 Wide geographic disparities characterize cancer across the US, with people living in high-
poverty areas more likely to be diagnosed with, and die from, numerous preventable cancers.1,2,52 
Some of largest disparities between low- and high-poverty areas are for cancers associated with 
human papillomavirus (HPV).1 Residents of high-poverty areas are nearly twice as likely to 
develop and die from cervical cancer as individuals in low-poverty areas.1,2 Incidence of HPV-
associated penile, anal, vaginal, vulvar, and oropharyngeal cancer are also 30-80% higher for 
those living in high-poverty areas.1 Geographic inequities in HPV cancer are complex and have 
been attributed to multiple, overlapping risk factors, including prevalence of higher risk HPV 
types and lower use of cervical cancer screening that can detect abnormalities at an earlier pre-
cancerous stage.3,4,53  
 In 2006, the introduction of HPV vaccine created an important new opportunity for cancer 
prevention, with the most recent formulation protecting against seven oncogenic types of HPV 
along with two types that cause genital warts.5 HPV vaccination has unprecedented potential to 
reduce the incidence of six cancers attributable to HPV most of which do not have effective 
screening options.54,55 Further, HPV vaccination has the potential to reduce disparities in cancer 
outcomes by providing accessible prevention at a low out-of-pocket cost.56 The potential benefits 
of HPV vaccine are so promising that several research and advocacy organizations believe the 
eradication of cervical cancer may be an achievable goal in the US.6,8,9 Whether this goal is 
equally achievable across high- and low-poverty areas remains unclear. 
 To date, several studies have shown that HPV vaccine initiation is higher in high-poverty 
areas11,57,58, but the long-term implications of this higher uptake for cancer disparities remains 
unclear.  However, studies modeling the long-term effects of HPV vaccine have focused on the 
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US as whole, potentially missing important geographic heterogeneity in HPV prevalence, 
cervical cancer screening rates, and pre-vaccine cancer incidence.17,47,54 This study uses a 
dynamic infection model, incorporating area-specific contextual factors, to understand the long-
term implication of current HPV vaccination patterns on HPV cancer incidence for low- and 
high-poverty counties in the US.   
Methods 
 
We used a dynamic infection model of HPV infection, transmission, and progression to 
cancer to reflect HPV transmission dynamics and cancer incidence. We incorporated inputs 
specific to both high-poverty and low-poverty counties to produce realistic reflections of both 
settings. We created a simulated population of one million heterosexual individuals and then 
used data on HPV vaccination to project forward the future cancer incidence in both a 
hypothetical high-poverty and hypothetical low-poverty county over a 75-year time horizon.   
HPV Transmission Model  
 
 We first developed a dynamic HPV transmission model using a susceptible-infected-
recovered-susceptible framework (Figure 2).59 The model describes separately the transmission 
and progression of seven types of oncogenic HPV which are vaccine protected (HPV 16, 18, 31, 
33, 45, 52, and 58) and a combined measure of all other high-risk HPV types. HPV cancers 
included in the model are cervical, vaginal, vulvar, penile, anal and oropharyngeal cancer. 
Parameters describing sexual transmission of HPV, the natural history of HPV cancers, vaccine 
efficacy, and natural immunity among those who cleared an HPV infection were derived from a 
review of the literature.14,17,27,60   
Natural history parameters were calibrated to fit pre-vaccination data on national estimates of 
HPV prevalence (from the NHANES 2003-2006)61 and HPV cancer incidence (from the 
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Surveillance, Epidemiology and End Results Program 2005)62. Additional information on model 
calibration approach is provided in the technical appendix.  
Model Inputs by Poverty Quartile 
We divided US counties in quartiles based on percent of residents living below 100% of 
the Federal Poverty Level (FPL), using the 2010 American Community Survey.63 Descriptive 
characteristics of counties in high- and low-poverty quartiles appear in Table 1. We matched the 
highest and lowest poverty quartiles with county-level data on fertility rates (among women age 
15-44) and sex- and age-specific mortality rates from the CDC Wonder database.64 Estimates of 
cervical cancer screening specific to high- vs. low-poverty counties came from a review of the 
literature.65 We used the National Immunization Survey—Teen to produce National estimates of 
HPV vaccination rates by age, sex, and year.66 We then modified these estimates to represent 
high- and low-poverty counties based on literature estimates of the relative risk of vaccination by 
area poverty.11,58,67 While several studies examined HPV vaccine initiation, few examined 
completion of the full series. We use an estimate from a single study which finds no difference 
by area poverty in completion of subsequent HPV vaccine doses58, however we examined the 
effect of both higher and lower vaccine follow-through in sensitivity analysis.   
Estimates of HPV prevalence by county-level poverty quartile were not available in the 
literature.  Therefore, we used type-specific prevalence of HPV by household poverty level from 
NHANES (2003-2006) to simulate county-level data using percent of each county living below 
the poverty threshold. These estimates were used to produce a population-weighted average of 
HPV prevalence, by type, at the county poverty quartile. A summary of poverty-specific model 
parameters appears in Table 2.  
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We incorporated poverty-specific population parameters, cervical cancer screening 
parameters, and starting HPV prevalence data into the dynamic transmission model to create 
separate high- and low-poverty models. HPV infectivity and natural immunity parameters were 
fixed at values used for the national model, as these are unlikely to vary significantly across 
counties, but sexual behavior, sexual assortiveness, and cancer progression variables were varied 
to calibrate each model to final HPV prevalence and cancer incidence data specific to each 
poverty quartile.  
Analysis 
We ran models representing both low- and high-poverty counties starting in 2005. Year, 
sex, and age-specific vaccination data were used to model uptake of HPV vaccine in each 
county. After 2017, we projected vaccination rates assuming annual rates of vaccine initiation 
and completion remain similar to their 2017 rates in future (Figure 3). We ran models using a 
simulated population of one million individuals per county using monthly time steps for 75 
years. We report annual age-adjusted HPV cancer incidence, as well as HPV cancers by sex and 
cancer site.  
While the vaccine has very high efficacy when all doses are delivered on schedule68,69, 
the efficacy of partial series completion remains uncertain.70–72  In base case analysis we assume 
only 50% protection for those who initiate, but do not complete, the full HPV vaccine series. 
However, we also examine two alternative scenarios, one assuming no protection from an 
incomplete series and a second assuming complete protection from a single dose of HPV 
vaccine.  Finally, we consider the long-term implications associated with lower or higher 
estimates of HPV vaccine initiation and follow-through in high-poverty areas. All analysis was 






Our model projects that current HPV vaccination rates will result in a dramatic reduction 
in HPV cancers over 75 years in both low- and high-poverty counties, with a projected 40.9% 
reduction in annual HPV cancer incidence for the low-poverty and a 42.0% reduction for the 
high-poverty setting (Figure 3). However, the relative risk of HPV cancer for a high-poverty 
relative to a low-poverty county is 1.51 in 2006 and is projected to decrease only slightly to 1.46 
by the end of the 75-year period.  
When findings were stratified by sex and cancer site (Figure 4; Table 3), we show that 
the bulk of this reduction will be for women- both in terms of absolute cancer reduction and the 
reduction in cancer disparities. Prior to the introduction of HPV vaccine, women living in high-
poverty counties had a relative risk for HPV cancers 1.57 that of those living in low-poverty 
counties. After 75 years, both low- and high-poverty counties we project nearly 50% decrease in 
HPV cancers, but the relative risk of cancer will remain similar at 1.51. The absolute cancer 
decrease among women is largest for cervical cancers, which is projected to decline 62% in high-
poverty and 60% in low-poverty settings. Again, the increased risk for high-poverty counties 
[RR: 1.82] narrows only slightly over this time period [at 75 years- RR: 1.74]. The largest 
disparity reduction is seen for vaginal cancer, which has a relative risk of 1.65 for women in 
high-poverty counties now but is projected to decline to a relative risk of 1.36 after by 2080. 
Overall cancer reductions for men are projected to be much smaller, with high-poverty counties 
seeing 1.7 fewer cancers per 100,000 (16% reduction) and low-poverty counties seeing 1.1 fewer 
cancers per 100,000 (17% reduction) after 75 years.  
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For men, we project that overall HPV cancer disparities will increase slightly (from 1.53 
RR to 1.54 RR; Figure 5). By site, we find that while incidence of each HPV is projected to 
decline, there will be a slight increase in oropharyngeal cancer disparities (from 1.56 RR to 1.57 
RR), a slight decrease in anal cancer disparities (from 1.66 RR to 1.49 RR), and a moderate 
decrease in penile cancer disparities (from 1.40 RR to 1.38 RR).   
We vary key model inputs in one-way sensitivity analysis to assess the effect these 
characteristics have on our projections (Table 4). Over a shorter time horizon, reductions in HPV 
cancer disparities for high vs. low settings are projected to be smaller, with a 1% reduction after 
25 years (a total reduction of 0.8 excess cases per 100,000) and a 4% reduction after 50 years (a 
total reduction of 2.3 excess cases per 100,000). When varying assumptions around the efficacy 
of partial series completion, our estimates remain stable. If those who initiate but fail to complete 
the HPV vaccine series receive no protection from the partial series, overall HPV cancer 
incidence after 75 years would be slightly higher, but the relative reduction in disparities remains 
the same (5%). Similarly, if protection is provided by at least one dose of HPV vaccine, both 
low- and high-poverty counties see further reductions in HPV cancer incidence but the relative 
reduction in disparities remains at 5%.  
Finally, we tested the magnitude of difference in HPV vaccine uptake between high- and 
low-poverty counties. Changing the relative risk HPV vaccine initiation for high- vs. low-
poverty counties to our lowest estimate resulted in a 3% reduction in disparities and changing to 
our highest estimate resulted in a 9% reduction (Table 4). Effects of changing follow-through 
assumptions were smaller with minimal changes in absolute cancer incidence after 75 years and 






Using dynamic transmission models, we find that that current vaccination patterns are 
projected to result in little or no reduction in HPV cancer disparities in high- vs. low-poverty 
counties. This finding is robust to changes in vaccine initiation and follow-through as well as 
changing assumptions about protection from an incomplete HPV vaccine series. While the 
magnitude of decrease varies as these inputs change, we find all of our scenarios result in a 
reduction in disparities by area poverty but none of our scenarios suggest this gap will fully close 
or even significantly reduce within the next 75 years.  
Reducing cancer disparities following the introduction of a new technology is relatively 
unique, as breakthroughs in cancer treatment and prevention often exacerbate existing 
inequity.74,75 However, numerous studies suggest higher uptake of HPV vaccine among 
traditionally underserved groups.11,76,77 Burger and colleagues have projected HPV vaccination 
to similarly reduce, but not eliminate, racial/ethnic disparities in HPV cancers.45 High uptake 
among traditionally underserved populations may be a result of numerous programs and policies 
designed to provide HPV vaccine at little or no out-of-pocket cost.78 Some have also suggested 
provider risk perception may play a role, as provider recommendation is the strongest predictor 
of vaccine receipt and providers may offer more frequent and stronger recommendations for 
patients they perceive risk to be at higher risk.79–81  
Yet, we find disparities in cancer incidence are likely to persist with a sizeable decrease 
in absolute magnitude but only a small change in the relative gap between high- and low-poverty 
counties. Consistent with the foundation work of Phelan and Link, contextual factors dominate 
even in the presence of effective interventions.82,83 High-poverty counties have fewer resources 
for preventive care, risk identification, and promotion of healthy behaviors that may reduce HPV 
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cancer risk.84,85  Due in large part to poor access, women in high-poverty areas have lower use of 
cervical cancer screening which may serve as important secondary prevention of cervical 
cancer.65,86 Those living in high-poverty settings are also more likely to have other risk factors 
for HPV cancers, including higher smoking rates, higher parity, and co-ocurring sexually 
transmitted infection.87–90  Further, high-poverty counties have a disproportionate representation 
of HPV types not protected against by current vaccines. Therefore, cancer control efforts should 
continue to focus on the full continuum of cancer prevention and control in order to ensure 
equity.50  
We note several limitations and strengths of our modeling approach. Firstly, we used 
cross-sectional data to estimate differences in HPV prevalence, HPV vaccination, and cervical 
cancer screening. This may underestimate trends over time, particularly if HPV vaccination 
differences in uptake between high- and low-poverty settings widen or narrow over the study 
period. When examining the impact of smaller or larger differences in vaccination, our 
conclusions are generally similar; however, more recent data on differences in vaccination by 
area poverty are needed. Secondly, while we can incorporate high and low-poverty-specific 
estimates for many of our key variables, we cannot observe all differences in HPV transmission 
and progression between a high- and low-poverty setting. We therefore rely on probabilistic 
model calibration to identify parameters sets that can plausibly reproduce observed pre-
vaccination disparities in HPV and HPV cancers. Richer data at the county level on sexual 
behavior, sexual networks, preventive care utilization, insurance status and other risk factors 
would help to improve model specification and increase confidence in model conclusions.  
Despite these limitations, our model produces overall estimates of HPV cancer reduction that is 
comparable to that seen in other studies54 while providing additional granularity on the effects in 
 
 19 
both low- and high-poverty settings. We also note that we are among the first studies to provide 
insights on the potential impact of partial series completion- an important contribution given 




In addition to its potential for cancer prevention, HPV vaccine offers an unprecedented 
opportunity to reduce the large and persistent disparities in HPV cancer between high- and low-
poverty areas. Current vaccination rates are projected to reduce but not eliminate the higher 
incidence of HPV cancers in high-poverty areas relative to low-poverty areas. HPV vaccination 
alone is unlikely to achieve equity in HPV cancer, therefore policy-makers and advocates should 
adopt multi-component strategies which seek to increase HPV vaccination in all settings while 
also increasing access to screening and primary care and addressing underlying social 




Tables and Figures:  
 
Table 1: Characteristics of Low- and High-Poverty Counties 
Characteristics  Low-poverty High-poverty 
Mean (sd)  n=785 n=785 
Percent <100% FPL 9.3% 25.1% 
 (1.9) (5.0) 
County Population 107,273 59,784 
 (225,774) (191,592) 
Percent Black  3.3% 19.1% 
 (6.0) (21.4) 
Percent Asian 1.8% 0.8% 
 (3.9) (1.4) 
Percent Native American 1.0% 3.9% 
 (3.1) (13.2) 
Percent Native Hawaiian/Pacific Islander 0.1% 0.1% 
 (0.6) (0.1) 
Percent Hispanic 7.1% 9.9% 
 (9.1) (18.1) 
Percent of County Living in a Rural Area 52.7% 77.4% 
 (49.9) (41.7) 
Percent Unemployed 3.3% 5.6% 
 (6.9) (5.4) 
Percent White Collar Employment 35.2 28.1 
 (1.4) (2.1) 
Area Deprivation Index 83.2 114.1 
 (20.8) (18.1) 
Income Disparity 2.08 3.47 
 (.396) (.401) 
FPL: Federal Poverty Level; the Area Deprivation Index is an 11-item measure, scaled such that 100 represents the 
median deprivation of US counties92; Income disparity measure is defined as the log of 100 x ratio of households 





Table 2: Input Data by Poverty Quartile 




Fertility Rate  
(births per 1,000 women age 15-45) 
65 74  CDC Wonder64 
Mortality Rate  
(Deaths per 100,000) 
Males Females Males Females  CDC Wonder64 
     <10 534 616 912 1088   
     10-13 12 14 15 25   
     14-17 28 61 33 109   
     18-24 53 142 64 198   
     25-34 72 167 138 257   
     35-44 125 207 275 399   
     45-54 282 434 541 810   
     55-64 585 949 983 1,642   
     65-74 1,394 2,035 1,923 2,972   
     75-84 3,870 5,304 4,671 6,497   
     85+ 13,500 15,434 14,126 15,993   
Cervical Cancer Screening  
Up-to-date 
  0.82  
[0.80- 0.85] 
Coughlin 200665 
HPV prevalence by type  
(among women age 18-64)  
   NHANES 2003-2006,  
ACS 201061,63 
     HPV 16 4.3% 4.8%   
     HPV 18 1.8% 2.0%   
     HPV 31 1.7% 1.8%   
     HPV 33 1.0% 1.1%   
     HPV 45 1.5% 1.7%   
     HPV 52 2.5% 2.7%   
     HPV 58 0.9% 1.1%   
     Other HR types 9.6% 10.2%   
HPV vaccine initiation 
(ages 11-17) 
  1.16  
[1.08- 1.42] 
Henry 2016, Henry 
2018, Pruitt 201011,58,67 
HPV vaccine follow-through 
(ages 11-17) 








Table 3: HPV Cancer Incidence by Sex, Site, and County Poverty Quartile  
 











Relative Risk   
Disparity 
Reduction 
Cervical 9.3 5.1 1.82 3.5 2.0 1.74 8% 
Vulvar 1.9 1.2 1.58 0.8 0.5 1.46 12% 
Vaginal 0.7 0.5 1.65 0.1 0.1 1.36 29% 
Oropharyngeal 8.1 5.7 1.42 5.2 3.6 1.44 -2% 
Anal 1.9 1.5 1.30 1.4 1.1 1.33 -3% 
All female cancers 21.9 13.9 1.57 11.0 7.3 1.51 6% 
Male        
Penile 0.6 0.3 1.66 0.2 0.1 1.49 17% 
Oropharyngeal 7.8 5.0 1.56 7.0 4.5 1.57 -1% 
Anal 2.0 1.4 1.40 1.3 1.0 1.38 2% 












Relative Risk  
(High vs. Low) 
Disparity 
Reduction 
Pre-vaccine  11.9 18.1 1.51  
Base Case    7.1 10.4 1.46 5% 
Time Horizon (Base Case: 75 years)   
After 25 Years 10.7 16.2 1.50 1% 
After 50 Years 8.2 12.0 1.47 4% 
Efficacy of Partial HPV Vaccine Series (Base Case 50% Protection of Full 
Series) 
 
Full Protection 6.5 9.5 1.46 5% 
No Protection  7.4 10.9 1.46 5% 
Vaccine Initiation High vs. Low-poverty (Base Case RR: 1.16)  
RR 1.08 7.1 10.5 1.48 3% 
RR 1.42 7.1 10.1 1.42 9% 
Vaccine Follow through High vs. Low-poverty (Base Case RR: 1.0)  
RR 0.84 7.1 10.4 1.48 3% 
RR 1.16 7.1 10.3 1.46 5% 
 
 
RR: Risk ratio; Incidence is annual age-adjusted HPV cancer incidence per 100,000 persons. Relative Risk 
represents the ratio difference between high and low-poverty HPV cancer incidence; Disparity reduction is defined 





Figure 2: Model Overview 
 
Summary of possible model states and transitions. Model states and transitions are separately calculated as 












Percent of 11-17 year-olds with >1 dose (initiation) and all required doses (completion). Solid line represents data 





Figure 4: Projected HPV Cancer Incidence in High- vs. Low-Poverty Counties After 
Introduction of HPV Vaccine  
 












Figure 6: Projected HPV Cancer Incidence, by Cancer Site: Males 
 
 














Introduction: HPV vaccination has the potential to prevent six types of HPV cancer, 
greatly reducing future morbidity associated with these cancers as well as future costs associated 
with workup and treatment. However, studies of HPV vaccine cost-effectiveness have only used 
national data, ignoring potentially important heterogeneity in pre-vaccination cancer prevalence, 
screening behavior, and risk factors.  
Methods: We created a dynamic transmission model of HPV infection and progression 
and populated it with inputs representing low- and high-poverty US counties. We incorporated 
poverty-specific differences in HPV prevalence as well as cervical cancer screening, competing 
mortality, and historic and projected HPV vaccine uptake. We evaluate a 10-percentage point 
increase in current vaccination rates in both types of counties and report total costs and benefits 
over a 75-year period as well as the incremental cost effectiveness ratio (ICER) for gains in 
quality adjusted life years (QALYs). Costs and QALYs are discounted at 3%.  
Results: We find that increasing HPV vaccination by is cost-effective in both high- and 
low-poverty settings, although the incremental benefit associated with increasing vaccination is 
larger in high-poverty areas. For a 10-percentage point increase in vaccination, high-poverty 
counties would see a reduction of 6.7 HPV cancers per 100,000 at an additional $221,494 per 
100,000 people, producing an ICER of $33,145. In low-poverty counties, the associated 
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reduction in HPV cancer incidence would be 4.4 cases per 100,000 at an incremental cost of 
$236,707, resulting in an ICER of $54,281. Sensitivity analysis found time horizon and discount 
rate were among the most influential model assumptions, with the cost-effectiveness of HPV 
vaccination severely diminished when considered over a shorter time or when future benefits 
were heavily discounted.  
Discussion: HPV vaccination is cost-effective, even for low-poverty areas with relatively 
low baseline HPV cancer burden. Importantly, the long-term benefits of HPV vaccine are even 
larger than previously estimated for high-poverty areas where the existing cost and morbidity 
burden of HPV cancers is high. The low cost of vaccination relative to its benefits – particularly 
in high-poverty settings- suggests considerable resources could be allocated to increasing HPV 








 The human papillomavirus (HPV) vaccine was first released in 2006.93 Originally a three-
dose series, it was shown to provide near-complete protection against four types of HPV.94,95 
Early modeling studies showed HPV vaccine is cost-effective for the prevention of genital warts 
and cervical cancer16,17, and it was recommended for girls ages 11-12, with catch-up vaccination 
from 12-26.96 Subsequent studies showed protection against vulvar and vaginal cancers in 
women20, as well as genital warts and anal cancers in men18,19, and in 2011 HPV vaccine was 
routinely recommended for both boys and girls ages 11-12.21 In 2015, a new version of the 
vaccine was introduced which protected against nine types - including types that together cause 
90% of cervical cancers worldwide, as well as a significant portion of vaginal, vulvar,  penile, 
anal, and oropharyngeal cancers.25 This new formulation was shown to be cost effective relative 
to the quadrivalent formulation27,28 and was added to Advisory Committee on Immunization 
Practices (ACIP) recommendations.26 The most recent change in ACIP recommendations 
occurred in 2016, when a two-dose schedule was shown to be both efficacious29 and cost 
effective31 and was recommended for boys and girl initiating the vaccine prior to age 15.97 
 Despite the clear evidence of benefits among both boys and girls, vaccine uptake has 
remained lower than targets. In 2017, only 65.5% of all adolescents had initiated the series and 
only 48.6% were up-to-date with all recommended doses.10 Further, there are wide geographic 
difference in uptake across the US- with patterns notably different from those of many other 
preventive services.57,98,99 Studies suggest areas with higher proportions of population living in 
poverty have higher initiation of HPV vaccine, a finding which may have important implications 
for disparities.11,58,67 Higher uptake in low resource areas also has implications for estimates of 
vaccine cost-effectiveness. Prior studies of cost-effectiveness have incorporated US average data 
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on baseline HPV cancer prevalence, cervical cancer screening patterns, and HPV vaccine 
uptake.15,17,49 High-poverty counties have a greater baseline risk of cancer1,3, lower use of 
preventive cancer screening65,86, and higher prevalence of numerous HPV cancer risk factors, 
including smoking and co-occurring infections87–90- creating an environment which may result in 
differential costs and benefits relative to lower poverty counterparts.  
 In a context of lower than expected uptake and changing HPV vaccine recommendations, it 
is important to re-evaluate the cost-effectiveness of increasing HPV vaccination within 
heterogenous contexts across the US. We use area-level, poverty- specific data on HPV 
prevalence, HPV cancer incidence, cervical cancer screening patterns, and HPV vaccine uptake 
to model the cost and benefits of increasing HPV vaccination rates in both a high-poverty and 
low-poverty setting over a 75-year period.  
Methods 
 
We examined the additional cost and cancer reduction associated with a ten-percentage 
point increase in HPV vaccination in both a high- and low-poverty county over a period of 75 
years using a societal perspective. To assess this difference, we used a dynamic model of HPV 
infection that accounts for county-specific differences in HPV cancer incidence, HPV 
prevalence, cervical cancer screening behavior, and baseline HPV vaccination.  We followed 
best practices for modeling of dynamic systems, as recommended by the International Society 
for Pharmacoeconomics and Outcomes Research.100  
Dynamic Transmission Model  
Assessments were performed using a compartmental dynamic HPV transmission model 
stratified by sex, age, and sexual activity level. Our model described separately the transmission 
and progression of eight categories of HPV infection, including seven vaccine protected viral 
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type shown to be oncogenic (HPV 16, 18, 31, 33, 45, 52, and 58) and one combined measure of 
all other high-risk HPV type. We described HPV transmission using sex transmission dynamics 
in a strictly heterosexual population following an overall model structure similar to that used in 
previous studies of HPV vaccination15,17,27 using transmission and progression inputs from the 
literature.14,17,27,60 Model outcomes included six HPV cancers; cervical, vaginal, vulvar, penile, 
anal, and oropharyngeal.  Full model details can be found in the technical appendix.  
Poverty-Specific Model Inputs  
Data from the American Community Survey were used to divide counties into quartile by 
percent of the county living below the Federal Poverty Level.63 Counties in the highest and 
lowest quartile of poverty were matched to data from CDC Wonder on fertility rates (among 
women 15-44) and mortality rates (by sex and age) to produce average inputs for each model.64 
Estimates of up-to-date cervical cancer screening by county poverty were derived from past 
studies.65 A multi-step calibration was performed by generating 10,000 sets of parameters from 
plausible ranges of uncertain variables using Latin Hypercube sampling,101 testing goodness-of-
fit against calibration targets using mean square error, and retaining the best fitting parameter set. 
HPV transmission variables were first calibrated to poverty-specific estimates of pre-vaccination 
data on HPV prevalence, derived from the 2003-2006 National Health and Nutrition 
Examination Surveys (NHANES).61 Once these inputs were determined, progression parameters 
for each cancer site were calibrated to poverty-specific data on cancer incidence.1,62  
Data on HPV vaccine initiation and completion rates for 2006-2017 were derived from 
provider-verified data using the National Immunization Survey—Teen and then modified to 
represent high- and low- poverty counties using relative risk estimates reported by previous 
studies.11,58,67  Efficacy of HPV vaccine when the full series is completed in near 100% for all 
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covered types.25 However, previous studies have varied widely in their assumptions regarding 
protection for those who initiate but do not complete the full HPV vaccine series.15,17,49 In our 
base case, we assume that those who initiate but fail to complete the HPV vaccine series have 
50% of the full vaccine efficacy, however we also examine full protection and no protection 
from an incomplete series.  
Cost and Utility Data  
Data on HPV vaccine cost – including cost for each HPV vaccine dose, wastage cost, and 
travel time were derived from previous studies15,17,49 and updated to 2018 dollars using the 
consumer price index.102 Estimated average treatment costs for each HPV cancer were also 
updated to 2019 dollars. To assess effectiveness of HPV vaccine, we applied an age-specific 
quality-adjusted life year (QALY) decrement for each HPV cancer outcome.60 Both costs and 
quality-adjusted life years were discounted at a rate of 3% per year according to best practices.103 
A summary of cost and QALY inputs is provided in Table 5.  
Analysis 
High- and low-poverty models were run for a 100-year stabilization period to produce 
realistic estimates of pre-vaccine HPV prevalence and HPV cancer incidence rates. To assess the 
cost and effectiveness associated with increasing HPV vaccination, we modeled a ten 
percentage-point increase (above 2017 rates) in HPV vaccine initiation in each setting and 
assessed the differences in costs, HPV cancer incidence, and QALYs over a 75-year period 
relative to vaccination as usual. We age-adjusted cancer incidence to a 2000 standard US 
population and report all outcomes per 100,000 population. We present the incremental cost 
effectiveness ratio (ICER- a ratio of intervention costs to benefits) using both incremental costs 
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per HPV cancer averted and incremental cost per QALY gained. We compare the ICER for 
QALYs gained to standard willingness-to-pay thresholds of both $50,000 and $100,000.103  
We further examined our results with several sensitivity analyses. Firstly, we report 
outcomes at shorter time horizons, including both 25 and 50 years. We also modified the 
discount rate to a low of 0% (undiscounted) and a high of 6%. We examined a range of HPV 
vaccination costs by varying our base estimates for cost of HPV vaccine, administration, and 
patient time up or down by 25%. To examine assumptions around protection from an incomplete 
HPV vaccine series, we report outcomes under both extremes of this variable- firstly a model in 
which no protection is provided by an incomplete HPV vaccine series (0% efficacy) and 
secondly a model in which an incomplete series provides identical protection to an incomplete 
one (100% the efficacy of a full series). Finally, as some evidence suggests one HPV vaccine 
dose could be sufficient for protection104, we assess the effect of a single-dose vaccine regimen 
over a 75-year period, which assumes identical efficacy for a single-dose vaccine but assumes 
only the cost of a single dose of HPV vaccine. All analysis was performed using R (version 
5.3.4).73 
Results 
 For those living in a low-poverty county, a ten-percentage point increase in HPV 
vaccination would result in in 4.4 fewer cases of HPV cancer per 100,000 over a 75-year time 
horizon. (Table 6) This increase in HPV vaccination would provide an additional 4.8 QALYs 
over this period at a cost of $236,707 per 100,000, resulting in an incremental cost per QALY 
gained of $49,854. For those living in high-poverty counties, an identical increase in HPV 
vaccination would result in a 53% larger reduction in cancer incidence over 75 years (6.7 cases 
per 100,000). Those in a high-poverty county would also see a larger benefit to HPV vaccination 
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in terms of QALYs gained (7.5 per 100,000) as well as a lower total cost over 75-years 
($221,494 per 100,000). While both counties would be below a willingness-to-pay threshold of 
$50,000 per QALY gained, the ICER associated with HPV vaccination in a high-poverty county 
would be nearly half that of a low-poverty county at $29,482 per QALY gained.  
 Comparing outcomes by sex and cancer site, our estimates show that this benefit would 
be concentrated largely in additional female cancers averted, with a projected reduction of 6.0 
HPV cancers per 100,000 in high-poverty and 3.8 HPV cancers per 100,000 in low-poverty 
counties over 75 years. Among males, reductions would be smaller and more similar across 
county settings, with a projected 0.7 fewer HPV cancers per 100,000 in a high-poverty and 0.6 
fewer HPV cancers in a low-poverty setting. (Table 7) 
 In sensitivity analyses, we first considered the time over which both costs and benefits 
were measured. (Figure 6) The cost-effectiveness of vaccination was diminished over a shorter 
time horizon- with an ICER of $87,784 for high-poverty county and $145,662 for a low-poverty 
county when costs and benefits are only considered over 25 years. A ten-percentage point 
increase in HPV vaccination would be associated with fewer than one additional HPV cancer 
averted per 100,000 persons in either setting over a 25-year period. When considering benefits 
over 50 years, cancer reductions are larger and ICERs are $29,482 and $63,352 per QALY 
gained for a high and low-poverty county, respectively. Finally, when increasing our time 
horizon to 100 years, additional improvements would be seen relative to a 75-year time horizon 
with ICERs of $27,498 per QALY gained in high-poverty and $46,069 per QALY gained in low-
poverty counties.  
 Changes in the discount rate of this period were also associated with wide variation in 
HPV vaccine cost effectiveness by setting. (Figure 7) If all costs and outcomes were valued 
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equally over time (a discount rate of 0%), the cost-effectiveness of the vaccine would be 
improved in both settings, to $9,774 per QALY gained in a high-poverty county and $19,745 per 
QALY gained in a low-poverty county. Increasing the discount rate to 6% per year resulted in 
both county types moving above a $50,000 per QALY gained willingness-to-pay threshold 
($67,795 per QALY gained in a high-poverty county and $107,933 per QALY gained in a low-
poverty county).  
 When changing model cost inputs, we found that even large changes in cancer treatment 
costs (+/- 50%) resulted in relatively small changes in cost-effectiveness (less than 15% change 
in the ICER estimate) due to the highly delayed nature of these outcomes. However, changes in 
costs for each HPV vaccine dose, administration, and patient time had a relatively large effect on 
vaccine cost-effectiveness. We test a range of cost per dose from $150 to $250. For high-poverty 
counties this produced a range of ICERs from $20,004 to $38,117 per QALY gained (Figure 7), 
while for low-poverty counties this produced ICERs that ranged from $35,031 to $63,279 per 
QALY gained.  
 Changing assumptions around partial series completion also had potentially meaningful 
effects on cost-effectiveness estimates. If initiating but failing to complete the series offers no 
additional protection, ICERs for high- and low- poverty counties would be $38,589 and $65,403 
per QALY gained over 75 years. If those who start but fail to complete the series receive full 
protection, HPV vaccine was more cost effective with an ICER of $26,491 for a high-poverty 
county and $45,271 for a low-poverty county.  
We additionally examined a scenario analysis considering the cost and cancer reduction 
associated with moving to universal adoption of a single-dose HPV vaccine. This change would 
substantially improve cost-effectiveness in both settings, with an ICER of $15,289 per QALY 
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National estimates likely underestimate the cost-effectiveness of HPV vaccination in 
high-poverty counties and overestimate the cost-effectiveness in low-poverty counties. Despite 
higher uptake at present in high-poverty settings, we find that increases in vaccination would still 
produce larger reductions in HPV cancers in high-poverty settings than in low-poverty settings- 
most notably through reductions in cervical cancers. Our base case estimates suggest HPV 
vaccination is cost-effective in both settings- therefore broad efforts to increase vaccination 
should continue. However, existing strategies for increasing HPV vaccination are associated with 
additional costs for outreach or implementation, which likely increase as the unvaccinated 
population becomes smaller.22,105 Thus, the cost-effectiveness of HPV vaccination has larger 
implications, suggesting how much programs to increase HPV vaccination could spend on such 
efforts while maintaining the overall cost-effectiveness of the program. 
We note that estimates of the cost-effectiveness of HPV vaccination in each setting are 
sensitive to changes in model inputs. Most notable among these are changes in the time horizon 
over which costs and benefits are allowed to accrue and assumptions about the rate at which 
future outcomes (both costs and benefits) are discounted relative to immediate outcomes. In the 
case that decision makers choose to not consider or heavily discount long-term outcomes, the 
cost-effectiveness of vaccination is less clear.   
Comparing our findings to those of previous modeling studies, we find that our 
estimation of HPV vaccine cost-effectiveness when delivered to both boys and girls is more 
favorable than previous estimates in the US.15,38 A large share of the difference is due to 
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changing HPV vaccination recommendations over time. Firstly, we examine the cost-
effectiveness of increasing uptake of the nine valent HPV vaccine which protects against 
additional types beyond those considered in early studies, improving long-term cancer 
prevention.27,37 Secondly, we consider the two-dose schedule, which results in substantially 
lower vaccine dose costs and higher follow-through compared to the three-dose schedule.106  
The cost-effectiveness of HPV vaccination may continue to improve as new vaccines 
cover more types, as more cancers are connected to HPV infection, and as dosing schedules or 
vaccine costs change. We provide insight into the implications of a single-dose vaccine- a policy 
change which many see as a next step in HPV vaccination.104  In the case that only one dose of 
HPV vaccine is sufficient for protection, there would be a large reduction in upfront cost with 
little or no change in long-term benefits, further improving the potential cost-effectiveness of 
HPV vaccination. 
There are several limitations to our modeling approach that should be considered. Firstly, 
we model average effects by county poverty quartile, which may miss heterogeneity of 
underlying risk, HPV prevalence, and vaccination rates within counties in high- and low-poverty 
quartiles. Second, while we expressly model differences in HPV cancer incidence between these 
counties, we use identical parameters across settings for treatment costs and quality of life after 
cancer onset, which may fail to reflect differences in treatment quality and HPV cancer mortality 
between high- and low-poverty settings. Finally, we note that we include only QALY and cost 
benefits associated with reduction in HPV cancers. HPV vaccination is also projected to greatly 
reduce the incidence and economic burden associated with genital warts- exclusion of this 
outcome likely results in an underestimation of the potential cost-effectiveness of HPV vaccine 
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in both counties.107  However, data on prevalence by county is insufficient to suggest whether 
this change would be differential by setting.  
Our modeling approach also has notable strengths, including the use of poverty-specific 
estimates of pre-vaccination HPV cancer incidence and HPV prevalence as well as HPV 
vaccination rates. We also provide insights on the implications of poor vaccine follow-through 
rates by showing how cost-effectiveness changes as assumptions around the efficacy of partial 
series completion changes- an assumption not varied in previous modeling studies.  
Conclusions 
 We show that variation in HPV cancer risk by area poverty has implications for the cost-
effectiveness of HPV vaccine. Increasing HPV vaccine uptake is cost-effective across all 
settings, but traditional approaches likely underestimate the cost-effectiveness of the vaccine in 
high-poverty settings where the baseline cost and morbidity burden of HPV cancer is much 
higher than US-average estimates.  Our findings suggest that efforts to increase HPV vaccination 
should continue in all settings, but that considerable resources could be dedicated to such efforts 




Tables and Figures 
 
Table 5: Model Inputs  
 
Vaccination Costs   Model Value Source 
HPV vaccine (per dose)  $170  Laprise 2016
31 
Patient Time  $30  Kim 2008
17 
Treatment costs per incident cancer  
Cervical $34,116  Kim 2009
23 
Vulvar $24,516  Kim 2009
23 
Vaginal $28,128  Kim 2009
23 
Penile $20,532  Kim 2009
23 
Oropharyngeal $44,844  Kim 2009
23 
Anal $37,596  Kim 2009
23 
Median QALYs lost per incident cancer  
Cervical               5.4  Brisson 2013
60 
Vulvar                4.4  Brisson 2013
60 
Vaginal                6.3  Brisson 2013
60 
Oropharyngeal (F)               6.8  Brisson 2013
60 
Anal Cancer (F)                5.0  Brisson 2013
60 
Penile Cancer               4.8  Brisson 2013
60 
Oropharyngeal (M)               5.0  Brisson 2013
60 
Anal (M)               6.6  Brisson 2013
60 
QALY- Quality-adjusted life year; All costs updated to 2018 US dollars; QALYs lost per incident cancer vary by 





Table 6: Costs and Cancer Reduction Associated with Increasing HPV Vaccination in Low 







Incremental costs $ 221,494   $ 236,707  
QALYs gained 7.5 4.8 
Cost per QALY $ 29,482   $ 49,854  
Cancers averted 6.7 4.4 
Cost per cancer case averted $ 33,145   $ 54,281  
   
QALY- Quality-adjusted life year; Incremental costs, QALYs, and cancer incidence are per 100,000 over a time 





Table 7: HPV Cancers Averted From a Ten Percentage-Point Increase in HPV Vaccine 








Cervical 2.6 1.5 
Vulvar 0.5 0.3 
Vaginal 0.3 0.2 
Anal 0.5 0.3 
Oropharyngeal 2.2 1.5 
All female cancers 6.0 3.8 






Penile 0.2 0.1 
Anal 0.5 0.3 
Oropharyngeal 0.04 0.1 
All male cancers 0.7 0.6 
 





Figure 7: Effect of Changing Time Horizon on ICER Estimates and Cancers Averted  
 
 
ICER- Incremental Cost Effectiveness Ratio; QALY- Quality-adjusted life year; 





Figure 8: Sensitivity of ICER to Changes in Key Model Inputs  
 
*Changes the relative protection associated with initiating HPV vaccine but failing to complete all recommended 
doses 
^Assumes recommendations changed to a single-dose vaccine which provides equivalent protection to current two-












Introduction: HPV vaccine offers substantial benefits for cancer prevention, yet 
vaccination rates still remain well below national targets. To achieve goals for long-term 
reductions in HPV cancer incidence, it is important to identify cost-effective methods for 
increasing HPV vaccine uptake.  
Methods: We used a dynamic infection model of HPV transmission and progression to 
estimate HPV cancer incidence over a 50-year period following a one-time, state level 
implementation of three simulated interventions for increasing HPV vaccination. Interventions 
compared were centralized reminder/recall, school-located vaccination, and the Center for 
Disease Control’s provider-focused intervention, Assessment, Feedback, Incentives, and 
eXchanges program (AFIX). Interventions were modeled based on literature estimates of reach, 
effectiveness, and per-person cost. Outcomes included additional individuals vaccinated, cancers 
averted, and quality-adjusted life years (QALYs) gained. Probabilistic sensitivity analysis varied 
all parameters simultaneously to assess a range of plausible outcomes associated with each 
intervention.  
Results: All three interventions were cost-effective relative to status quo vaccination at a 
willingness-to-pay threshold of $50,000 per QALY gained. AFIX offered the lowest total cost 
($64,855) and was also associated with the lowest cost per additional HPV vaccine delivered 
($14), cost per cancer case averted ($758), and cost per QALY gained ($257). School-located 
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vaccination resulted in the greatest projected increase in vaccination (25,493 additional 
individuals vaccinated), reduction in HPV cancer (327 cases averted vs. no intervention) and 
increase in quality of life (1,044 QALYs gained vs. no intervention) at a cost that was below a 
$50,000 per QALY-gained willingness-to-pay threshold (WTP) when compared to all 
alternatives. Probabilistic sensitivity analysis using a WTP of $50,000 per QALY gained 
suggested school-located vaccination was preferred in 93.7% of all scenarios, reminder/recall 
was preferred in 5.6% and AFIX was preferred in less than 1%.  
Conclusion: All three strategies reach standard thresholds for cost-effectiveness relative 
to no intervention. AFIX offers a low cost and efficient intervention, but both reminder/recall 
and school-located vaccination can achieve further gains for additional costs. Policy makers who 
want to increase HPV vaccine uptake will need to consider tradeoffs between feasibility, total 









 Human papillomavirus (HPV) causes significant morbidity and mortality in the US as the 
causal agent for nearly all cervical cancers as well as the majority of anal, penile, vaginal, vulvar, 
and oropharyngeal cancers.108 The 2006 introduction of HPV vaccine offered unprecedented 
potential for reducing not only cancer mortality, but also incidence of many cancers attributable 
to HPV.55 The reduction in cancer incidence is expected to be particularly dramatic in cervical 
cancer, leading the American Association of Cancer Research and other organizations to declare 
the eradication of cervical cancer an achievable goal.6,8,9 Yet, despite the potential benefits of 
HPV vaccination, uptake remains low. In 2017, only 69% of girls and 63% of boys ages 11-17 
had received at least one dose, and 50% of girls and 38% of boys were up-to-date with all 
recommended doses.10  
A considerable literature has examined strategies to increase vaccination among children 
and adults, but less is known about effective strategies for doing so among adolescents.109,110 
School entry laws have proven effective for several adolescent vaccinations, including tetanus-
diphtheria-pertussis, meningococcal vaccine, and hepatitis B.111 Interventions proven to be 
successful in other vaccination settings have been adapted and tested for increasing initiation and 
completion of HPV vaccine, including interventions to address barriers in access, as well as 
targeting both patient and provider factors.36 However, direct comparison of these interventions 
for short-term vaccination uptake is limited, and no studies have explored the long-term 
implications of these interventions for cancer prevention.   
To make progress towards the stated goal of eradicating cervical cancer, as well as to 
reduce the burden of other HPV-associated cancers, policy-makers and advocates are 
appropriately focused on improving HPV vaccination rates. To support these efforts, empirical 
 
 49 
guidance is needed on which strategies offer the highest reduction in HPV-associated cancers at 
the lowest relative cost. Our study uses a decision modeling approach to simulate, at a 
population-level, three evidence-based interventions to increase HPV vaccination rates and 
assesses the long-term cost-effectiveness of each compared to no intervention, as well as to each 




We created a compartmental, dynamic model of HPV infection, transmission, and 
progression to cancer in a heterosexual US population. We used this model to compare cost, 
cancer incidence, and quality-adjusted life years associated with a statewide implementation of 
each of three evidence-based interventions for increasing HPV vaccination vs. no intervention 
(vaccination as normal) over a 50-year time horizon. The study was conducted following best 
practices as described in the Consolidated Health Economic Evaluation Reporting Standards.112 
Full model detail can be found in the technical appendix.  
HPV Transmission Model Overview 
 The model begins with 5,000,000 individuals – the median population size of a US state,  
stratified by sex and age to represent the US population.63 Individuals enter the model at age zero 
according to estimated fertility rates and progress through eleven non-overlapping age groups 
where they may die of competing disease at age- and sex-specific mortality rates.64  Sexual 
transmission of HPV is based on a Susceptible-Infected-Recovered-Susceptible framework59 
which we use to separately describe seven vaccine-protected types of HPV (16, 18, 31, 33, 45, 
52, and 58) and a single combined estimate of high-risk types not protected by the vaccine. 
Those infected with HPV who do not recover naturally may progress at type-, sex-, and age-
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specific rates to one of six HPV-associated cancer types (cervical, vaginal, vulvar, penile, anal, 
and oropharyngeal).  
HPV vaccine has high efficacy against covered types when completed at the 
recommended schedule,68,69 but the extent of protection when the series is partially complete 
remains unclear.70–72 Therefore, we modeled three vaccination states; unvaccinated, vaccine 
initiated, and vaccine completed, with the assumption that those who initiated but failed to 
complete the vaccine series receive only partial protection (50% of the efficacy values used for 
the full series). Sensitivity analysis examined complete protection (100% of the efficacy values 
used for the full series) and no protection when series was initiated but not completed.  
Model Input Data 
Model inputs were estimated directly from large national data sources when available and 
supported by literature estimates when necessary. Data on population age structure, births, and 
deaths were obtained from 2010 Census Data.63 Data on sexual behavior, type-specific 
infectivity rates, and vaccine efficacy were obtained from existing HPV modeling 
literature.14,17,27,60 Age- and type-specific HPV prevalence data were generated using population-
weighted estimates from the National Health and Nutrition Examination Survey (NHANES).61 
Finally, data on HPV vaccine initiation and follow-through by age, sex, and year were derived 
from population-weighted, provider-verified estimates using the 2006-2017 National 
Immunization Survey—Teen (NIS—Teen).66  
Base case model inputs were varied in probabilistic model calibration to pre-vaccine 
HPV prevalence (NHANES) by type and age and HPV cancer incidence by sex, site, and age 
using estimates from the Surveillance, Epidemiology and End-Results Program (SEER).61,62 
Further information on model calibration is provided in the technical appendix. 
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Comparison Interventions  
 Following an intervention taxonomy described by Briss and colleagues110, we evaluate 
one intervention in each of three categories; increasing community demand for vaccination 
(centralized reminder/recall), enhancing access to vaccination (school-located vaccination) and 
provider-based interventions (CDC’s Assessment, Feedback, Incentives, and eXchanges 
program—AFIX).  We assumed a state-level implementation of each intervention and scaled all 
intervention characteristics accordingly. We modeled a one-time, year-long implementation of 
each intervention. Population-level impact of each intervention is determined by a combination 
of two factors. Reach describes the total number of individuals potentially exposed to the 
intervention (both vaccinated and unvaccinated) while effectiveness describes the impact of the 
intervention on HPV vaccination rates among unvaccinated individuals exposed to the 
intervention. As reach is generally proportional to the total cost of an intervention, we use studies 
with intervention cost data to estimate both a feasible reach for each intervention and the 
expected per-person cost for the intervention at the state level. Data on the effectiveness of each 
decision alternative by age and sex come from randomized controlled trials; additional data on 
best and worst-case scenarios are collected from single-arm studies. We describe each 
intervention briefly below and present summary of target population, reach, effectiveness, and 
cost of each intervention in Table 8.  
Centralized Reminder/Recall 
Centralized reminder/recall uses a regional or state-based immunization information 
system that stores vaccination information from health departments and participating 
providers.113 Data from the immunization registry are used to contact parents or caregivers of 
individuals aged 11 to 17  who will be due for an HPV vaccine dose (reminder) or who are 
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overdue for an HPV vaccine dose (recall) and provide these individuals and/or their parents with 
information to make an appointment with their primary care providers. The resources involved in 
reminder/recall are staff time and intervention materials (including reminder letters).114,115 
Studies suggests these methods are effective for increasing HPV vaccine initiation in both boys 
and girls,76,116,117 and the use of recall likely also results in increased follow-through of the 
series.118–120  
School-Located Vaccination 
 In a school-located vaccination model, parents provide consent for sixth to eight-grade 
teens (ages 11-14) to be vaccinated by trained community vaccinators during one or more visits 
to the school, generally timed in accordance with recommended vaccine schedules.121,122 Costs 
for school-located vaccination include time and resources involved in creating information 
materials, obtaining permission from parents, clinic set-up, vaccination time, and time spent 
processing claims for insured adolescents as well the cost of vaccine doses for individuals who 
uninsured and not eligible for subsided vaccine doses.123 Studies suggest substantial 
improvement in vaccination coverage for both girls and boys when both groups are offered the 
program as well as increases in follow-through above national averages.123–125  
Assessment, Feedback, Incentives and eXchange Program 
The AFIX intervention is an in-person or webinar-based provider training that facilitates 
goal setting, provides information on best-practices for increasing vaccination rates, and provides 
clinics with detailed information about their vaccination rates at their practice.126 Costs for AFIX 
are those associated with travel and staff time for conducting a training either in person or 
online.127,128 AFIX is associated with a significant increase in HPV vaccine initiation among 
those ages 11-12, but data on increases among those 13-17 are mixed.129–131 Small but non-
 
 53 
significant increases in follow-through have been observed in both younger and older age 
groups.129,131 We consider no increases in follow-through for our base case model but add 
modest increases in a best-case scenario. Effectiveness data has generally focused on increasing 
vaccination among girls, but a study including boys found the increase for this group was similar 
or slightly larger in absolute magnitude to that seen in girls.130      
Outcome Measures 
 We consider total intervention cost from the perspective of a state government in 2018 
US dollars. As all intervention costs are assumed to occur in the first year, these are not 
discounted. We do not include savings resulting from increased vaccination as the state 
government would not directly bear these costs in the future. We also report the number of 
additional individuals initiating the HPV vaccine series and completing all recommended HPV 
vaccine doses, total cases of HPV cancer averted and total quality-adjusted life years (QALYs) 
gained over a 50-year time horizon. QALYs associated with each intervention alternative are 
calculated using a sex- and age-specific decrements associated with incidence of HPV cancer15 
and were discounted at a rate of 3% per year.  
Analysis 
 Using identical starting conditions, we simulate vaccination, transmission, and cancer 
progression for 50 years assuming a one-time implementation of each of the comparison 
interventions.  To assess the cost-effectiveness of each strategy in terms of individuals 
vaccinated, cancers prevented and QALYs gained, we calculate incremental cost effectiveness 
ratios comparing each intervention to no intervention as well as sequentially comparing each 
outcome with its next best alternative.   
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We perform both deterministic and probabilistic sensitivity analyses to assess the 
robustness of our findings to changing model inputs. First, we compare for each alternative a 
“best case” which uses the highest effectiveness and lowest cost estimate and “worst case” 
scenario using the low end of effectiveness and the high end of costs. Then, to create a plausible 
range of intervention outcomes, we vary all cost and effectiveness parameters, using a Monte 
Carlo sampling approach to draw cost and effectiveness values for each unknown parameter 
from within the range of estimates seen in the literature. We graph the incremental cost and 




 Compared to no intervention, each intervention scenario resulted in an increase in the 
total number of individuals vaccinated (additional 4,699 for the AFIX program, 6,994 
individuals for reminder/recall, and 18,724 for school-located vaccinations; Table 9) as well as 
reductions in total cancer incidence (86 fewer cases for the AFIX program, 105 for 
reminder/recall, 327 for school-located vaccination) and gains in QALYs (an additional 252 
QALYs for the AFIX program, 359 for reminder/recall, and 1,044 for school-located 
vaccination). Total intervention costs for the state were $64,885 for the AFIX program, $972,825 
for reminder/recall and more than $3 million for implementation of a school-located vaccine 
program. 
 We compare intervention sequentially to determine the cost-effectiveness of each against 
the next best intervention. We find that relative to no intervention, AFIX costs an additional 
$758 per cancer averted and an additional $257 per QALY gained. Beyond the gains achievable 
by the AFIX intervention, the use of a centralized reminder/recall program could avert an 
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additional 20 cancers and gain an additional 107 QALYs at the expense of an additional 
$907,970 (Incremental Cost/Effectiveness Ratio (ICER): $8,462 per QALY gained). For highest 
benefit at highest cost, a school-located vaccination program would avert an additional 222 
cancers beyond a reminder/recall intervention, gain an additional 685 QALYs, and cost an 
additional $2.1 million (ICER: $3,018 per QALY gained). This value is well under the 
commonly used willingness-to-pay thresholds103, suggesting a statewide implementation of 
school-located vaccination would be the preferred approach.  
Comparing best- and worst-case scenarios from literature-based estimates shows 
considerable variability in both the absolute and relative effectiveness as parameter inputs 
change (Table 10). Using the most optimistic inputs (lower cost, higher effectiveness) we find 
that each intervention improves in its cost-effectiveness, and but that school-located vaccination 
continues to be the preferred option (ICER: $2,041 per QALY gained). However, when 
intervention inputs are changed to the lowest effectiveness and highest cost reported in the 
literature, our conclusion changes. Compared to AFIX, reminder/recall costs an additional $1.6 
million yet results in 0.2 fewer QALYs over 50 years, making it a dominated strategy. As it is no 
longer a relevant comparator, we compare school-located vaccination to AFIX and find a gain of 
67 QALYs at an additional cost of 2.1 million- resulting in an ICER of $54,969. At a 
willingness-to-pay threshold of $50,000 per QALY gained, this would suggest school-located 
vaccination is not cost effective and AFIX should be considered the preferred strategy.  
We further describe this variability using probabilistic sensitivity analysis to vary all 
input parameters simultaneously. While there is no overlap in the expected cost of the three 
interventions, there is moderate overlap in the potential QALYs gained from implementation of 
each, with a particularly wide uncertainty on the effectiveness of school-located vaccination 
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(Figure 8). We find that using a willingness-to-pay threshold of $50,000 per QALY gained, 
93.7% of our scenarios suggest school-located vaccination is the preferred intervention, 5.6% 
suggest reminder/recall is preferred, and only 0.7% resulted in AFIX being preferred to both 
other options.  
In pairwise comparisons, we find uncertainty increases but recommendations generally 
remain the same. If comparing only between reminder/recall and AFIX, while always more 
expensive, we find reminder/recall is cost-effective in 83.4% of scenarios. (Figure 9) When 
comparing school-located vaccination and AFIX, we find that despite always costing an 
additional $2 million or more, school located vaccination is cost-effective in 98.1% of scenarios. 
When removing AFIX from the considered options, we find that school-located vaccination is 
preferable to reminder/recall 94.1% of the time. (Figure 10) 
Discussion 
Using a dynamic model of HPV infection, we find a statewide implementation of a 
school-located vaccination to generally be a cost-effective approach to increasing HPV 
vaccination. This conclusion is subject to some limitations, as model results were somewhat 
sensitive to changes in cost and effectiveness of each intervention. In a scenario where all 
interventions inputs are set to the lower end of reported values, school-located vaccination fails 
to achieve enough benefit to outweigh its high cost.  Centralized reminder/recall offers a lower 
cost, less intensive alternative that may be preferred in settings where school-located vaccination 
is infeasible or unlikely to achieve effective results.   
 Effective interventions typically involve tradeoffs between intensive, highly effective 
strategies with limited scope and broad interventions with wider reach but a smaller effect at the 
individual level. While the AFIX program offers only modest increases in vaccination rates, by 
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targeting providers, it offers a wider population impact for minimal cost.127 School-located 
vaccination, on the other hand, requires intensive resources but has been shown to be effective in 
certain settings.122,123,125 Given the high potential of HPV vaccine for public health benefit28,54, 
we find even the relatively high cost of the school-located vaccination program is generally 
under established willingness-to-pay thresholds when considered over a 50-year time horizon. As 
no groups have yet met Healthy People 2020 goals for HPV vaccination35, it is likely that large-
scale interventions will continue to be preferred to more targeted approaches.36 
While all three approaches have been shown to increase vaccination across various age 
groups and settings109,110, data suggest HPV vaccination may present a unique challenge for 
increasing vaccine uptake. For example, reminder/recall interventions have an estimated median 
effect of seven percentage points across other adolescent vaccines113 but have shown only a two 
to six percentage point increase in HPV vaccination.117,120 Similarly, qualitative work has shown 
parents report greater hesitancy regarding school-located HPV vaccination than school-based 
delivery of other vaccines.132 As such, implementation of school-located vaccination has proven 
challenging due to lack of buy-in from both parents and administrators.133,134 Those interested in 
implementing HPV vaccination strategies should consider the challenges particular to the 
vaccine as well as setting-specific challenges.105,124,127,134  
These findings should be interpreted in light of limitations of existing intervention 
evidence, model simplifications, and project scope. First, because vaccination was only broadly 
recommended for boys starting in 2011, evidence is much richer for increasing HPV vaccine 
uptake in girls. Second, we used costs and reach associated with previous implementations of 
each interventions, which may vary by setting in ways we cannot capture here. Third, we made 
several simplifications when modeling HPV infection. Notably, we only consider heterosexual 
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transmission of HPV, a simplification made in nearly all models of HPV infection54. We also 
note our model structure does not allow for the consideration of co-occurring infections, which 
may miss the additive or multiplicative effect of infection with multiple types concurrently.  
We also note that our model only considers each intervention’s benefits for HPV 
vaccination and HPV cancers from the perspective of a state or local government agency. As 
such, we do not include vaccine costs nor do we include cost-savings associated with future 
cancers. Additionally, each intervention may be associated with the receipt of other adolescent 
vaccines associated through increased primary care attendance or improved provider practices. 
Inclusion of these considerations would likely increase the cost-effectiveness of each 
intervention and may or may not alter the relative differences across approaches. 
Conclusion 
 HPV vaccination rates remain relatively low, at rates insufficient to achieve the goal of 
eradicating cervical cancer or reaching full potential for reduction of all HPV cancers. Policy 
makers wishing to achieve wide gains at low cost should consider funding statewide AFIX 
interventions. Policy makers willing to dedicate significant resources to increasing vaccination 
should consider funding a statewide centralized reminder/recall or school-located vaccination 
intervention, which offer higher vaccination and increased QALYs gained at increasing costs 
relative to AFIX. To achieve national targets for vaccination, combinations of interventions or 
large-scale policy change may be necessary.  
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Tables and Figures 
Table 8: Summary of Intervention Characteristics 











11 to 13-year-olds in 
participating schools 
11 to 17-year-olds with 
participating providers 
Expected Reach    
      11 to 13-year-olds 275,500 247,254 246,500 
      14 to 17-year-olds 242,250 0 216,750 
Vaccination Rate (%)    
Expected improvement in HPV Vaccine initiation Ratea 
      Females 11-13 2.0% [1.0%, 6.0%] 13.0% [2.0%,17.7%] 2.6% [0.9%,4.2%] 
      Males 11-13 5.0% [1.0%, 6.0%] 13.0% [2.0%,17.7%] 2.6% [0.9%,3.1%] 
      Females 14-17 3.0% [1.9%, 6.0%] -- 0.0% [0.0%,3.3%] 
      Males 14-17 2.0% [0.3%, 6.0%] -- 0.0% [0.0%,8.0%] 
Expected improvement in HPV Vaccine follow-through Rateb 
      Females 11-13 8.0% [0.0%,16.6%] 4.0% [0.0%,18%]  0.0% [0.0%,1.3%] 
      Males 11-13 8.0% [0.0%,16.6%] 4.0% [0.0%,18%] 0.0% [0.0%,1.3%] 
      Females 14-17  8.0% [0.0%,16.6%] -- 0.0% [0.0%,1.3%] 
      Males 14-17 8.0% [0.0%,16.6%] -- 0.0% [0.0%,1.3%] 






 aEstimated percentage point increase in vaccination in unvaccinated individuals. 
bEstimated percentage point increase in vaccine follow-through rates in vaccine initiators 





























 AFIX  $64,855 4,699 4,699 $14 86 86 $758 252 252 $257 
Reminder/Recall $972,825 6,994 2,295 $396 105 20 $45,880 359 107 $8,462 
School-located 
Vaccination  
$3,038,752 18,724 11,730 $176 327 222 $9,311 1044 685 $3,018 
Worst Case 
 AFIX  $97,283 1,627 1,627 $60 30 30 $3249 88 88 $1107 
Reminder/Recall $1,714,025 2,127 500 $3,233 30 0.1 $16,167,425 88 -0.2 dominated 
School-located 
Vaccination  
$3,797,821 2,881 754 $2,764 53 23 $91,595 155 67 $54,969 
Best Case 
 AFIX  $41,693 9,091 9,091 $5 124 124 $336 383 383 $109 
Reminder/Recall $616,123 12,517 3,426 $168 154 30 $19,296 533 150 $3,842 
School-located 
Vaccination  
$2,279,682 25,493 12,977 $128 394 240 $6,930 1348 815 $2,041 
 
Note: AFIX- Assessment, Feedback, Incentives, and eXchanges Program; QALY- Quality-adjusted life year; Costs and QALYs discounted at 











Figure 9: Incremental Cost and QALYs Gained  
 
 
Compares 200 Monte Carlo simulations of cost and quality-adjusted life years gained for each intervention 
compared to no intervention scenario. Relative to no intervention, all estimate are cost-effective at a 





Figure 10: Incremental Cost and Effectiveness of the AFIX Program Compared to 
Alternative HPV Vaccine Interventions  
 
 
Incremental costs and quality-adjusted life years associated with centralized reminder/recall and school-located 





Figure 11: Incremental Cost and Effectiveness of a School-Located Vaccination Program 




Incremental costs and quality-adjusted life years associated with school-located vaccination relative to centralized 










CHAPTER 5: DISCUSSION AND POLICY IMPLICATIONS 
Overview  
HPV vaccine offers unprecedented potential to prevent six HPV cancers, all of which are 
more common in high-poverty (vs. low-poverty) areas of the US. Using dynamic models of HPV 
transmission and progression, we show that current vaccination patterns are insufficient to 
meaningfully reduce area poverty disparities in HPV cancers. Fundamental cause theory suggests 
that disparities are not easily overcome by single interventions because the larger context which 
created the disparity continues.82  Area poverty disparities in cervical cancer are often attributed 
to differences in screening behavior86, yet wide socioeconomic and geographic disparities exist 
even for HPV cancers that are not screen-detectable, suggesting other system characteristics are 
contributing to differential cancer risk for these populations.1 Our evidence supports this 
hypothesis and suggests further work is needed to understand the complex system in which these 
disparities arise.135 
Inequity within the US is mirrored by global divides in HPV implementation. In some 
countries, uptake of HPV vaccine has been near-universal due to low barriers to access, provider 
buy-in, and school mandates.136 In contrast, uptake of HPV vaccine has been dismally low in 
other countries where media outrage or lack of provider endorsement have promoted vaccine 
hesitancy among parents.137 In high income countries with successful HPV vaccine programs, 
cervical cancer is likely to be eliminated within the next 50 years.32,138 Yet, those countries with 
the highest burden of HPV cancers are unlikely to see this scope of benefit. Even if HPV 
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vaccination were massively scaled up in these settings, a modeling study of country-level 
disparities in HPV cancers finds HPV vaccine alone would be insufficient to close the gap.33 
Taken together, these suggest that a multicomponent approach is needed to address area 
poverty disparities – both globally and domestically. As strategies are developed for elimination 
of cervical cancer as a public health problem, researchers emphasize the importance of 
improving screening protocols- both to reduce the over-screening of low risk women and 
improve the ability to reach and screen women at high risk.9,44,139 Identifying and addressing risk 
factors for HPV cancers that are not detectable through routine screening will also be important. 
Among the known risk factors are smoking and co-occuring sexually-transmitted 
infections88,90,140, both important public health priorities, particularly among underserved 
populations.  
We also find strong evidence that HPV vaccination – beyond having even greater 
potential for cancer reduction in areas of high need- may also be more cost-effective than 
previously thought for these settings. While further increasing HPV vaccination rates is cost-
effective in both low- and high-poverty counties, the cost per QALYs gained from vaccination is 
much lower for vaccination in a high-poverty area. Similar increases in vaccination in both high- 
and low- poverty models produce 50% greater reductions in future HPV cancer incidence for 
high-poverty counties. This suggests that efforts to increase HPV vaccination should continue for 
all counties, but that these efforts are likely to be associated with higher-than-expected returns in 
high-poverty areas. 
Studies have shown that the marginal cost for increasing HPV vaccination rates increases 
as uptake becomes higher.22 While HPV vaccination rates are still low in the US- particularly 
relative to other adolescent vaccines10, improving uptake may be a resource intensive exercise, 
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given the slow increases in vaccination to date. The Task Force on Community Preventive 
Services considers several categories of population-based interventions for improving 
vaccination110; increasing community demand for vaccination, enhancing access to vaccination, 
and provider-based intervention. We compare the costs and potential benefits associated with 
interventions representative of each of these categories and find that each offers tradeoffs 
between cost and effectiveness, with school-located programs offering the highest increase in 
vaccination at highest cost.  
These programs present an interesting case study of intervention intensity, with 
increasing effectiveness closely tied to increasing costs. AFIX offers a relatively low-cost 
intervention at the provider level, with a small but wide effect.129 Of the interventions we 
consider- AFIX is arguably the most scalable, with successful statewide AFIX programs already 
implemented for childhood vaccinations.141 Reminder/recall interventions are shown to be 
effective and can be delivered at lower per person costs when centralized using an immunization 
registry. Large, multi-county trials of centralized reminder/recall have proven to be feasible and 
effective, suggesting potential for an effective statewide implementation, particularly in states 
where robust immunization information systems already exist.114,142 School-located vaccination 
on the other hand has less evidence to support the feasibility of a statewide implementation. 
Intervention studies typically include fewer than 10 schools and effectiveness varies widely 
between studies.124 Researchers have also found community resistance to be a barrier to effective 
implementation of school-located programs.124,134 Yet, while resource intensive, we find that the 
majority of estimates suggest a sufficient effect that if a school-located vaccination program 
could be implemented at a state-level, it would maintain cost-effectiveness at all but the most 




 Our results suggest increasing HPV vaccination should continue as a key public health 
priority, particularly in areas with historically high rates of HPV associated cancers. We find that 
vaccination alone will likely be insufficient to eliminate HPV cancer disparities and that state 
Cancer Prevention and Control programs should continue to support multicomponent strategies 
to reduce HPV cancers. Our results underscore the importance of programs like the Breast and 
Cervical Cancer Screening Program which offers screening and treatment to low-income women 
who may be among the most vulnerable.143 For addressing disparities in all HPV cancers, 
however, an emphasis on fundamental causes, including healthcare access, smoking, and 
reproductive health education and access to preventive care is recommended.  
 Yet, while we note that HPV vaccine is insufficient to eliminate disparities, we do find a 
differential benefit in counties with high-poverty. A similar increase in HPV vaccination is 
projected to prevent nearly 50% more cancers in a high-poverty county, making vaccination even 
more cost effective in this setting than national estimates previously suggested. Numerous state 
and federal programs cover the cost of HPV vaccine to ensure it is available to individuals at no 
out-of-pocket cost. Given the high health benefits and low cost of HPV vaccine, programs with 
flexibility to do so should consider devoting additional resources to HPV vaccine outreach, 
particularly in traditionally underserved communities.   
 Finally, we find that Statewide efforts to increase HPV vaccination are likely to be cost-
effective at varying levels of intensity. School-located vaccination is resource intensive, yet is 
generally shown to have a large enough impact that a statewide implementation would be under 
standard cost-effectiveness thresholds compared to alternatives. For policy-makers concerned 
about the feasibility of school-located vaccination, we find that centralized reminder/recall 
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interventions may be the next best alternative. Finally, while the AFIX intervention is generally 
not the preferred intervention of the three by cost-effectiveness standards, we note that it offers 
the lowest cost per individual vaccinated and a high feasibility for Statewide implementation. 
States interested in improving HPV vaccination rates should consider the context of intervention 
implementation and the resources available, as all three interventions are cost-effective strategies 
relative to status quo.   
Future Directions   
 We consider several potential directions for future work. Firstly, while our work provides 
additional granularity on the effect of HPV vaccination on disparities by county poverty, we 
acknowledge the use of poverty quartiles does not capture the full heterogeneity of HPV cancer 
disparities in the US. In particular, a better understanding of the role of rurality in HPV cancer 
disparities may merit further investigation. The NIS—teen reports that those living in rural areas 
have lower HPV vaccine uptake than those in urban areas but that higher uptake among low-
poverty individuals is seen in both rural and urban contexts. As rural poverty may differ from 
urban poverty in numerous ways, future work should consider the impact of HPV vaccination on 
the interaction between poverty and rurality, as well as identifying strategies to reduce high HPV 
cancer rates in these areas.  
 Secondly, we acknowledge limitations of our model that may be improved upon in future 
work. As with the majority of HPV transmission models, we consider only heterosexual 
transmission of HPV, which may lead to biased estimates of HPV cancer- particularly if uptake 
of HPV vaccine, prevalence of HPV, or distribution of other risk factors differs for sexual 
minorities. In future work, we hope to be able to incorporate more granularity in sexual 
transmission estimates.  
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 Finally, studies of interventions to improve HPV vaccine uptake are disproportionately 
concentrated in low-poverty, urban settings. Few studies have examined how context of these 
interventions may be related to overall effectiveness, so we are unable to consider separately the 
impact of these interventions in high- and low-poverty settings. The few implementation studies 
that exist suggest community buy-in as well as support of administrators and clinicians involved 
is key.127,134,144 Understanding the contextual factors associated the success of alternative 
intervention strategies will be important for making community-specific recommendations for 





We used a dynamic, compartmental model to describe the population level transmission 
and progression of HPV in the context of current vaccination patterns. HPV infection was 
modeled using a susceptible-infected-recovered-susceptible (SIRS) framework. We calculated 
infection simultaneously for 7 high-risk HPV types that are protected against by the nonavalent 
HPV vaccine (HPV 16, 18 ,31 ,33 ,45 ,52, 58) and a combined category of high-risk types not 
protected against by current vaccines (including HPV 35, 39, 51, 56, 59, 66, and 68). Model 
outcomes included incident cases of eight HPV cancers- cervical, vaginal, vulvar, penile, anal, 
and oropharyngeal and lost quality-adjusted life years associated with each of these cases.  
In this appendix, we first discuss the model structure in detail; consisting of 4 
interconnected modules; demography, HPV vaccination, HPV transmission, and HPV 
progression. We next describe the process for calibration of the model to HPV prevalence and 




The model used an open population with the structure based on the US population in 
eleven non-overlapping age categories, stratified by sex. These estimates were derived using data 
from the 2010 census145 (Table A1) and scaled to the appropriate population size. 
 
Table A1: Population age structure by sex 
Age Group Females Males 
<10 6.4% 6.7% 
10-14 3.3% 3.4% 
15-17 2.0% 2.2% 
18-24 4.9% 5.1% 
25-34 6.6% 6.7% 
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35-44 6.7% 6.6% 
45-54 7.4% 7.2% 
55-64 6.1% 5.7% 
65-74 3.8% 3.3% 
75-84 2.5% 1.8% 
85+ 1.2% 0.6% 
Total 50.9% 49.2% 
 
Individuals exit the population due to all-cause mortality, with model inputs stratified by 
sex and age according to data from CDC Wonder64 (Table A2). New individuals enter the 
population at each time cycle according to estimates of annual fertility rate among women 14-45 
years of age (64.1 per 1,000 women).64 Individuals enter at <10 years of age and transition 
sequentially through subsequent age categories until they exist due to incident cancer or death.  
 
Table A2: Death rate per 100,000 by age and sex (annual) 
 Female Male 
<10 years 199.1 240.9 
10-14 years 12.1 16.3 
15-19 years 28.1 69.6 
20-24 years 44.8 126.4 
25-34 years 64.0 141.5 
35-44 years 128.9 212.5 
45-54 years 311.4 505.9 
55-64 years 643.5 1075.5 
65-74 years 1527.5 2275.1 
75-84 years 4137.7 5693.7 





 All individuals begin the model unvaccinated and initiate HPV vaccine at a sex-, age-, 
and year-specific rate using the provider-verified vaccination data from the National 
Immunization Survey—Teen (2006-2015).66  Vaccination in this model is represented by three 
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possible states; first individuals move from unvaccinated to the vaccine initiated state according 
to probabilities of having at least one dose of HPV vaccine. Secondly, individuals move to a 
vaccine completed state according to the probabilities of completing the series among those who 
initiated the series (follow-through).   
 
Figure A1: Summary of Model Vaccination States 
 
Cross-sectional prevalence of initiation and completion by age 13 and by age 17 were 
used to determine the annual probability of initiation and follow-through by age group (Table 
A3). For projecting forward, past years when survey data are available, we assumed the rate of 
initiation from 2017 would continue forward in future years, which results in equilibrium 
reached at 76% initiation for girls; 79% initiation for boys and 64% completion for girls; 72% 
completion for boys. For years prior to 2016, three doses of HPV vaccine were required for a full 
series. After 2016, only two doses are required as long as the vaccine is initiated prior to 
reaching age 15. The change in dosing schedule may result in increased vaccine follow-through, 
however we only have one year of data representing follow-through after this change took effect 
(2017) which may not be sufficient to observe the full benefit.  Therefore, we note our model 











 For those who have completed the full series, protection is life-long and type-specific 
using previously estimated vaccine efficacy (Table A4).27 For those who have initiated but not 
completed the series, we assume only partial protection in the base case analysis (50% the 
protection offered by the full series) and alter this assumption in sensitivity analysis.  
 
Table A3: Type-Specific Efficacy of Quadrivalent and Nonavalent HPV Vaccine  
 
Type Efficacy 4v Efficacy 9v 
16 99% 99% 
18 100% 100% 
31 46.2%* 95.5% 
33 -- 99.1% 
45 -- 96.8% 
52 -- 97.3% 
58 -- 94.8% 











 Viral transmission is dependent on two factors; type-specific infectivity and rates of 
exposure to infected individuals via sexual contact. Sexual behavior dynamics are be modeled 
following structures and assumptions used in previous studies, including modeling only 
heterosexual transmission.15,17,37 Broadly, the risk of acquiring a new HPV infection in any time 
period is a function of number of new partners during the time period, the rate of HPV infection 
among likely sexual partners (assuming sexual partner selection is strongly but incompletely 
assortive by age), and the infectivity of a given HPV type (Figure A3).  
 




 Individuals entering the model are sorted into one of four levels of sexual activity based on 
sex and age-specific probabilities (Table A5).17,147 Age and sexual activity level together 
determine the number of new sexual partners acquired each year (Table A6). The preference for 
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individuals within one’s own age category is termed assortiveness, where assortiveness of 0 
suggests that individuals find partners exclusively within their own age group while 
assortiveness of 1 suggests that mixing is completely random. We use an assortiveness of 0.3 for 
primary analysis but examine a range from 0.1 to 0.5.15,17,60  
Table A4: Sexual Activity Category by Sex and Age 
 
 Sexual activity  
Age (years)  Very Low  Low Moderate High 
FEMALES      
10-14  0.94 0.06 0 0 
15-17  0.502 0.331 0.07 0.097 
18-19  0.171 0.506 0.136 0.188 
20-24  0.087 0.656 0.126 0.132 
25-29  0.025 0.803 0.094 0.077 
30-34  0.018 0.858 0.056 0.068 
35-39  0.01 0.865 0.061 0.064 
40-49+  0.013 0.886 0.034 0.067 
MALES      
10-14  0.94 0.06 0 0 
15-17  0.524 0.314 0.084 0.077 
18-19  0.247 0.423 0.162 0.168 
20-24  0.09 0.559 0.127 0.224 
25-29  0.047 0.738 0.066 0.149 
30-34  0.027 0.795 0.068 0.111 
35-39  0.019 0.842 0.05 0.09 
40-49+  0.018 0.836 0.055 0.092 
Number represents proportion of a given age group estimated to be in each sexual 
activity category. Data from Kim 200817; Barnabas 2006147 
 
Table A5: Number of New Partners Annually, by Age and Sexual Activity Category 
 Sexual Activity Category 
Age (years)  Very Low  Low Moderate High 
FEMALES      
10-14  0.48 1.34 3.5 15 
15-17  0.14 0.38 0.96 17.5 
18-19  0.14 0.38 0.96 17.5 
20-24  0.08 0.21 0.67 15 
25-29  0.06 0.15 0.35 10 
30-34  0.04 0.16 0.45 7.5 
35-39  0.04 0.08 0.45 7.5 
40-49+ 0.03 0.08 0.45 7.5 
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MALES      
10-14  0.38 1.1 2 12.5 
15-17  0.38 1.1 2 12.5 
18-19  0.14 0.39 1.4 15 
20-24  0.08 0.25 0.83 12.5 
25-29  0.06 0.17 0.5 10 
30-34  0.04 0.11 0.27 8.5 
35-39  0.04 0.1 0.33 7.5 
40-49+  0.03 0.1 0.33 7.5 
Data from Kim 200817; Barnabas 2006147 
 
 To determine risk of viral exposure, the sexual mixing equation is used to multiply the 
fraction of HPV- infected individuals (I) within each of eleven total age groups (a) by the 
probability of choosing a partner from within that age group (assortiveness, 𝜀) and the rate of 
sexual partner change (𝑘𝑗). Exposure to each HPV type is then multiplied by the type-specific, 
per-partnership infectivity rate (𝛽-Table A7) to determine the fraction of susceptible individuals 
within each sex/age/sexual activity category who are newly infected.27 The rate at which 
susceptible individuals are potentially infected by each HPV type is describe as the force of 
infection (), such that:  
𝜆𝑠 = 𝛽𝑠 ∗ 𝑘𝑗 ∗ (1 − 𝜀 ∗ (
𝐼𝑎′,𝑖′
𝑁𝑎′,𝑖′







))                                    [1] 
Where s=HPV type, a=age, i=sex, j=sexual activity category , a’=partner age, i'=partner sex 
 
 Table A6: Per-Partnership Infectivity Rate, by HPV Type 
HPV Type Infectivity (calibration range) 
HPV 16 0.79 (0.59 – 1.00) 
HPV 18 0.82 (0.62 – 1.00) 
HPV 31 0.75 (0.56 – 0.95) 
HPV 33 0.84 (0.63 – 1.00) 
HPV 45 0.64 (0.48 – 0.80) 
HPV 52 0.72 (0.54 – 0.90) 
HPV 58 0.76 (0.57 – 0.95) 
Other high-risk types 0.70 (0.53 – 0.90) 
Data from Durham, 201627 
   
 
 77 
 Data on HPV prevalence by age and separately by type was obtained from the 2003-2004 
NHANES, prior to the introduction of HPV vaccine (Table A8).61 To avoid over-estimates, 
individuals with co-occuring infections are only counted once, for the most virulent of their 
concurrent HPV types. NHANES only collects data on 18-69-year-olds, therefore infections for 
those below and above this age threshold are extrapolated from the available age ranges.  
 
 
 Table A7: Prevalence of HPV by Type and Age  
 HPV Type 
Age Group 16 18 31 33 45 52 58 Other 
<10 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
10-13 1.5% 0.6% 0.6% 0.4% 0.5% 0.9% 0.3% 3.3% 
14-17 3.0% 1.3% 1.2% 0.7% 1.1% 1.7% 0.7% 6.7% 
18-24 6.0% 2.6% 2.4% 1.5% 2.2% 3.5% 1.4% 13.3% 
25-34 4.4% 1.9% 1.8% 1.1% 1.6% 2.5% 1.0% 9.7% 
35-44 3.2% 1.4% 1.3% 0.8% 1.2% 1.9% 0.7% 7.1% 
45-54 3.5% 1.5% 1.4% 0.9% 1.2% 2.0% 0.8% 7.6% 
55-64 3.2% 1.4% 1.3% 0.8% 1.1% 1.8% 0.7% 7.0% 
65-74 2.1% 0.9% 0.9% 0.5% 0.8% 1.2% 0.5% 4.7% 
75-84 1.4% 0.6% 0.6% 0.3% 0.5% 0.8% 0.3% 3.1% 




 Individuals infected with HPV may clear the virus naturally, remain infected, or progress to 
an HPV-associated cancer (Figure A4.a). Model outcomes include the incidence of six HPV 
cancers; cervical, vaginal, vulvar, penile, anal, and oropharyngeal. Modeling of cervical cancer 
includes additional pre-cancerous states (Figure A4.b). Rates of clearance are determined by sex 
and viral type as well as by age, with older individuals less likely to clear infections (sTable 9). 
Individuals clearing an HPV infection are assumed to develop a partial, temporary, and type-
specific natural immunity. We assume this immunity wanes at a rate of 10% per year and use 




Figure A4: Summary of HPV Progression 
 




Natural History- HPV-associated cancers 
 Rate of progression from HPV to vaginal, vulvar, penile, anal, or oropharyngeal cancer is 
determined by HPV type, age, and sex (Table A9). Incident cancer is an absorbing state and no 
further outcomes are modeled. Progression from HPV infection to each cancer type was 
calibrated based on incidence of each cancer and the type-specific HPV attributable fraction.60 
This process is discussed in further detail in the calibration section of this appendix.    
Table A8: Annual progression rates by HPV Type and Cancer Site 
Vaginal Vulvar Anal Penile Oropharyngeal 
Type F F F M M  F M 
16 1.2e-4 2.0e-4 1.4e-5 1.2e-5 6.9e-5 2.4e-6 5.7e-5 
18 1.0e-5 5.8e-5 2.0e-5 2.0e-5 7.7e-6 1.0e-6 8.6e-5 
31 - 7.0e-5 1.0e-5 1.0e-5 2.0e-6 - 0 
33 - 3.0e-4 2.0e-5 2.0e-5 7.7e-6 2.1e-3 6.3e-4 
45 - 2.9e-5 - - 7.7e-6 - - 
52 - - - - 2.0e-6 - - 
58 1.0e-5 - - - 3.8e-6 - - 
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Other - 2.9e-5 1.0e-4 1.0e-4 1.2e-6 1.0e-4 1.0e-4 
Modifier 
(<25) 
0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Modifier 
(age 45+) 
1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Modifier 
(age 65+) 
2 2 1.7 1.7 2 1.7 1.7 
 
Natural History- cervical cancer  
 Similarly, infected females may progress from infection to Cervical Intraepithelial 
Neoplasia (CIN-1 and CIN-2,3) at a rate determined by both viral type and age, with older 
individuals more likely to progress and less likely to naturally clear cervical lesions.17,148,149  As 
with other HPV cancers, cervical cancer is an absorbing state in the model and no subsequent 
cancer treatment or outcomes are modeled.  

















HPV 16 0.55 0.09 0.33 0.17 0.18 0.11 0.58 
HPV 18 0.58 0.09 0.35 0.13 0.18 0.23 0.64 
HPV 31 0.60 0.09 0.33 0.04 0.18 0.08 0.33 
HPV 33 0.60 0.09 0.33 0.04 0.18 0.08 0.33 
HPV 45 0.60 0.09 0.33 0.04 0.18 0.08 0.33 
HPV 52 0.60 0.09 0.33 0.04 0.18 0.08 0.33 
HPV 58 0.60 0.09 0.33 0.04 0.18 0.08 0.33 
Modifier 
(age <25) 
1.2 0.7 1.2 0.7 1.2 0.7 - 
Modifier 
(age 45+) 
0.5 1.2 0.5 1.2 0.5 1.2 - 
Modifier 
(age 65+) 
0.7 1.4 0.7 1.4 0.7 1.4 - 
  
 In addition to spontaneous recovery from CIN-1 and CIN-2,3 states, individuals may have 
abnormalities detected via routine cervical cancer screening and successfully treated before they 
progress to cervical cancer.139 The probability of recovering via treatment is a function of 
cervical cancer screening rates, sensitivity of Pap smear to detect CIN-1 or CIN-2,3 abnormality, 
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probability of following-up for further testing after an abnormal screening, and the likelihood 
that treatment is successful, which may result in a complete clearance of infection (or clearance 
of intraepithelial neoplasia, but a return to the infected state (Table A10).23,27 Data on cervical 
cancer screening rates by age were obtained from the 2015 National Health Interview Survey. As 
self-report of vaccination has been shown to over-estimate actual rates of screening, inputs have 
been adjusted using the sensitivity and specificity of self-report. 150,151,152   
 Sensitivity of screening for CIN1 and CIN2,3 lesions, setting-specific rates of follow-up 
when test is abnormal, loss to follow-up, and success rates of treatment for CIN, are obtained 
from a review of the literature.17,27,60,153,154   
Table A10: Cervical Cancer Screening Parameters 
Parameter Estimate 
Annual Probability of Cervical Cancer Screen   
     Age 18-24  10.1% 
     Age 25-34  21.8% 
     Age 35-44  20.0% 
     Age 45-54  18.7% 
     Age 55-64  16.3% 
Lost to Follow-Up After Abnormal Screen  10.0% 
Pap Smear Sensitivity - CIN-1  70.0% 
Pap Smear Sensitivity - CIN-2,3  80.0% 
Co-testing Sensitivity- CIN-1  89.0% 
Co-testing Sensitivity- CIN-2,3  96.0% 
Lesion Treated, return to Infected  15.0% 







  To ensure our model could reasonably reproduce pre-vaccination rates of HPV cancers, 
we used probabilistic model calibration to find the combination of parameters that resulted in the 
best fit to historic HPV prevalence and cancer incidence data. A stepwise calibration approach 
was used to limit the number of potential targets being matched at single time. First, parameters 
were calibrated to fit pre-vaccine HPV prevalence data from 2005-2006 NHANES data.61 
Estimates of type-specific prevalence by age group are unreliable from the NHANES, so we 
calibrated simultaneously to two sets of targets; first prevalence of any HPV type by age and 
secondly type-specific prevalence among all 18-64-year-olds.  
We used Latin Hypercube sampling to generate 10,000 random draws from within the 
distributions provided for each of the 201 input parameters most closely related to sexual 
transmission of HPV including number of new sexual partners per year, type-specific infectivity, 
natural clearance rates, relative protection from natural immunity, the rate at which natural 
immunity wanes, and age-assortiveness of sexual partner selection.101 Results from each of the 
resulting 10,000 model replications were compared to targets using a root mean squared error 
approach and the best fitting parameter set was retained.  
After a plausible fit to HPV transmission parameters was obtained, parameters describing 
the progression from HPV infection to each of six HPV-associated cancer types were separately 
calibrated, using an identical approach to that used for HPV prevalence parameters. Data on 
cancer incidence came from SEER, with data on the HPV attributable-fraction of each cancer 




Table A11: Calibrated Parameters and Calibration Targets 
 Parameters varied (n) Calibration targets (n) Source of 
Calibration 
Data 
HPV Transmission Infectivity (8)  
New partner rate (88)  
HPV clearance (88)  
Natural immunity protection (8)  
Waning of immunity (1)  
Assortiveness (1)  
 
Total (194) 
HPV prevalence by type 
among 18-64-year-olds (8)  
 









Progression from Infection to CIN-1 
(88)  
Progression from CIN-1 to CIN-2,3 
(88)  
Progression from CIN-2,3 to cervical 
cancer (88)  
 
Regression from CIN-2,3 to CIN-1 
(88)  




Cervical cancer incidence by 














Vaginal and Vulvar 
Cancer  
Progression from infection to vaginal 
cancer (33)  
 




Vaginal cancer incidence by 
age (8)  
 
Vulvar cancer incidence by 






Progression from infection to penile 
cancer (88)  
 
Total (88) 
Penile cancer incidence by 






Progression from infection to anal 
cancer- female (55)  
 
Progression from infection to anal 
cancer- male (55) 
 
Total (110) 
Anal cancer incidence by 
age- female (8)  
 
Anal cancer incidence by 







Progression from infection to 
oropharyngeal cancer- female (44)  
 
Progression from infection to 
oropharyngeal cancer- male (44) 
 
Oropharyngeal cancer 
incidence by age- female (8)  
 
Oropharyngeal cancer 









We present model fit data from the final best-fitting parameter set, with final model fit compared 
to calibration targets with 95% confidence intervals (Figure A5:A8).  



























= (𝑏 ∗ 𝑆𝑎,𝑖=𝑓𝑒𝑚𝑎𝑙𝑒) − (𝑚𝑎,𝑖 ∗ 𝑆𝑎,𝑖) − (𝑤 ∗ 𝑆𝑎,𝑖) + (𝑤 ∗ 𝑆𝑎−1,𝑖) − (𝜂𝑠,𝑣 ∗ 𝜆𝑎,𝑖,𝑗,𝑠 ∗ 𝑆𝑎,𝑖,𝑣)




= (𝑤 ∗ 𝐼𝑎−1,𝑖,𝑗,𝑠,𝑣) − (𝑤 ∗ 𝐼𝑎,𝑖,𝑗,𝑣,𝑠) + (𝜂𝑠,𝑣 ∗ 𝜆𝑎,𝑖,𝑗,𝑠 ∗ 𝑆𝑎,𝑖,𝑣) − (𝛾0𝑎,𝑖,𝑠 ∗ 𝐼𝑎,𝑖,𝑗,𝑠,𝑣) −
(𝛾1𝑎,𝑠 ∗ 𝐶𝐼𝑁1𝑎,𝑗,𝑠,𝑣) + (𝛾4𝑎,𝑖,𝑠 ∗ 𝐶𝐼𝑁1𝑎,𝑗,𝑠,𝑣) + (𝛾6𝑎,𝑠 ∗ 𝐶𝐼𝑁2,3𝑎,𝑗,𝑠,𝑣) − (𝜋4𝑎,𝑠 ∗ 𝐼𝑎,𝑗,𝑠,𝑣) −
(𝜋5𝑎,𝑠 ∗ 𝐼𝑎,𝑗,𝑠,𝑣)  − (𝜋6𝑎,𝑠 ∗ 𝐼𝑎,𝑗,𝑠,𝑣) − (𝜋7𝑎,𝑠 ∗ 𝐼𝑎,𝑗,𝑠,𝑣) − (𝜋8𝑎,𝑠 ∗ 𝐼𝑎,𝑗,𝑠,𝑣)                                              
Cervical Intraepithelial Neoplasm Stage 1:  
𝜕𝐶𝐼𝑁1𝑎,𝑗,𝑠,𝑣
𝜕𝑡
= (𝑤 ∗ 𝐶𝐼𝑁1𝑎−1,𝑗,𝑣,𝑠) − (𝑤 ∗ 𝐶𝐼𝑁1𝑎,𝑗,𝑠,𝑣) + (𝜋1𝑎,𝑠 ∗ 𝐼𝑎,𝑗,𝑠,𝑣) − (𝛾1𝑎,𝑠
∗ 𝐶𝐼𝑁1𝑎,𝑗,𝑠,𝑣) + (𝛾2𝑎,𝑠 ∗ 𝐶𝐼𝑁2,3𝑎,𝑗,𝑠,𝑣) − (𝜋2𝑎,𝑠 ∗ 𝐶𝐼𝑁2,3𝑎,𝑗,𝑠,𝑣) − (𝛾3𝑎,𝑖,𝑠
∗ 𝐶𝐼𝑁1𝑎,𝑗,𝑠,𝑣) − (𝛾4𝑎,𝑖,𝑠 ∗ 𝐶𝐼𝑁1𝑎,𝑗,𝑠,𝑣) 
Cervical Intraepithelial Neoplasm Stage 2 or 3:  
𝜕𝐶𝐼𝑁2,3𝑎,𝑗,𝑠,𝑣
𝜕𝑡
= (𝑤 ∗ 𝐶𝐼𝑁2,3𝑎−1,𝑗,𝑣,𝑠) − (𝑤 ∗ 𝐶𝐼𝑁2,3𝑎,𝑗,𝑠,𝑣) + (𝜋2𝑎,𝑠 ∗ 𝐶𝐼𝑁1𝑎,𝑗,𝑠,𝑣) − (𝛾2𝑎,𝑠
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